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Summary 
 
Hepatocellular carcinoma (HCC) is the fifth most common cancer and third most lethal 
cancer worldwide. It is commonly associated with viral hepatitis, chronic exposure to 
toxins and hereditary liver diseases. The prognosis of patients with HCC is dismal and 
the mortality rates are almost the same as the incidence rates. Surgical resection or 
local ablation of the tumor provides the best results for patients with limited disease. 
Therapeutic options for patients with advanced disease are still sobering and even 
combinations of cytotoxic drugs such as doxorubicin, cisplatin, irinotecan and/ or 5-Fu 
produce only modest anti-tumor activity. The multikinase inhibitor Sorafenib has shown 
survival benefits in some patients with advanced HCC proving that molecular therapies 
can be effective in this devastating disease. These results have triggered the search 
for additional molecular agents to further expand patient survival.  
 
Recent studies revealed that the PI3K/mTOR kinase pathway is frequently deregulated 
in HCCs suggesting that it might play a pivotal role in hepatocarcinogenesis. 
PI3K/mTOR kinases are mainly involved in the regulation of cell proliferation, 
metabolism and survival. Although preclinical studies have shown that rapamycin and 
its analogous are potent inhibitors of tumor cell proliferation, the roles of specific down-
stream pathways of mTOR have been poorly defined. Additionally, it is important to 
note that broad-based use of mTOR inhibitors has not been as effective as initially 
anticipated, although many trials are still underway. One reason for this might be due 
to the fact that multiple mTORC1 dependent feedback loops exist to regulate the 
activation of upstream components of the network. The aim of this study was therefore 
to identify new strategies to improve mTOR directed therapies. 
 
In the first part of this study, the effect of RAD001 (mTOR inhibitor) an analogue of 
rapamycin, NVP-BKM120 (PI3K inhibitor) and NVP-BEZ235 (PI3K/mTOR inhibitor) 
alone and in combination with each other was studied. In addition, combination 
treatment of the above mentioned PI3K/mTOR inhibitors with the chemotherapeutic 
drugs doxorubicin, cisplatin, 5FU and irinotecan was analyzed in Huh7 cells in vitro and 
in xenograft mouse model. Inhibition of PI3K by novel drug NVP-BKM120 led to a more 
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potent tumor growth inhibition compared to RAD001 and NVP-BEZ235. Furthermore, 
dual PI3K/mTOR inhibition with NVP-BEZ235 is more effective as compared to 
RAD001 treatment alone. Next, the effect of the molecular drugs in combination with 
doxorubicin, cisplatin, 5-FU or irinotecan on cancer cell viability was tested. 
Interestingly, the combination of RAD001, NVP-BEZ235 and NVP-BKM120 with 
irinotecan or cisplatin was particular useful to decrease survival of Huh7 cells. These 
data provide evidence that mTOR inhibition is an effective strategy to increase 
sensitivity of hepatoma cells to conventional chemotherapeutic drugs suggesting that 
combination therapies with PI3K/mTOR and chemotherapeutic drugs could be a 
feasible option for non-cirrhotic HCC patients with good liver function. 
 
Though mTOR inhibitors and chemotherapeutic drugs are tested as therapeutic agents 
in HCC, the development of resistance to these drugs remains an important clinical 
problem. Therefore it is of great interest to understand the key oncogenic markers and 
their mechanisms that drive resistance in HCC. In the second part of this study, an in 
vitro system was therefore established to perform a genome-wide shRNA screen to 
identify genes that mediate resistance or sensitivity to mTOR directed therapies. In 
order to validate the screening approach, the effect of a shRNA-mediated knockdown 
of FKBP12 was analysed on the anti-tumor effects of RAD001. RAD001 potently 
reduced phoshorylation of P-S6, which was almost completely prevented in cells 
pretreated with a shRNA directed against FKBP12. Furthermore, knockdown of 
FKBP12 by RNA interference abolished the RAD001 induced growth arrest in vitro 
indicating that shRNA-mediated knockdown of functionally important target genes can 
be used to identify molecular mechanisms underlying RAD001 sensitivity or resistance. 
 
Key words: 
 
HCC - Hepatocellular carcinoma 
mTOR - mammalian Target Of Rapamycin 
PI3K - Phospho Inositide 3 Kinase 
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Zusammenfassung 
 
Das „Hepatozelluläre Karzinom“ (HCC) ist die fünft häufigste Krebserkrankung und die 
dritt häufigste krebsbedingte Todesursachen der Welt. In vielen Fällen tritt es zum 
Beispiel assoziiert mit einer viralen Hepatitis, im Zusammenhang mit chronischer 
Toxin-Exposition oder bedingt durch hereditären Lebererkrankungen auf. Die 
Prognose für HCC Patienten ist dabei gemeinhin sehr bedrückend und wird von einer 
sehr schlechten Mortalitätsrate und Inzidenz begleitet. Die chirurgische Resektion oder 
lokale Ablation des Tumors bietet in diesem Zusammenhang die besten Resultate für 
Patienten mit einer limitierten Erkrankung. Die therapeutischen Möglichkeiten für 
Patienten im fortgeschrittenen Stadium der Erkrankung sind bisher leider noch 
ernüchternd und selbst Kombinationen von Zytostatika wie Doxorubicin, Cisplatin, 
Irinotecan und/ oder 5-FU haben lediglich eine geringe Anti-Tumor-Aktivität. Sorafenib, 
ein Multi-Kinase-Inhibitor, war allerdings im Stande das Überleben einiger Patienten 
mit einem fortgeschrittenen Stadium des HCC zu erhöhen. Dies zeigt, dass molekulare 
Therapien, auch in Bezug auf diese verheerende Krankheit, Wirkung zeigen können. 
Diese Ergebnisse haben die Suche nach zusätzlichen molekularen Wirkstoffen, die 
das Überleben der Patienten fördern, weiter angeheizt. 
 
Jüngste Studien konnten zeigen, dass es im Rahmen des HCCs oft zu 
Fehlregulationen des PI3K/mTOR Kinase Signalwegs kommt. Dies deutet darauf hin, 
dass dieser Mechanismus vielleicht eine entscheidende Rolle für die 
Hepatokarzinogenese spielt. Die PI3K/mTOR Kinasen sind vor allem an der 
Regulation der Zellproliferation, des Stoffwechsels und des Überlebens beteiligt. 
Obwohl präklinische Studien gezeigt haben, dass Rapamycin und analoge 
Substanzen potente Inhibitoren der Proliferation von Tumorzellen sind, wurde die 
Rolle spezifischer down-stream Wege von mTOR bisher schlecht definiert. Darüber 
hinaus ist es allerdings auch wichtig zu beachten, dass breit angelegte Studien von 
mTOR-Inhibitoren bisher nicht so effektiv waren wie ursprünglich erwartet. 
Nichtsdestotrotz sind aber auch noch weitere aktuelle Studien zu diesem Thema im 
Gange. Ein Grund dafür könnte die Tatsache sein, dass mehrere mTORC1 abhängig 
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Feedback-Schleifen die Aktivität vorgelagerter Komponenten des Netzwerks regeln. 
Das Ziel der hier vorliegenden Studie war es daher, neue Strategien zur Verbesserung 
einer mTOR gerichteten Therapien zu finden. 
 
Im ersten Teil dieser Studie wurde die Wirkung von RAD001 (mTOR-Inhibitor), einem 
Analogon von Rapamycin, NVP-BKM120 (PI3K-Inhibitor) und NVP-BEZ235 
(PI3K/mTOR-Inhibitor) allein und in Kombination untersucht. Darüber hinaus wurde 
eine Kombinationsbehandlung der oben genannten PI3K/mTOR Inhibitoren mit dem 
Chemotherapeutikum Doxorubicin, Cisplatin, 5FU und Irinotecan in Huh7 Zellen in 
vitro und in einem Xenotransplantat Mausmodell untersucht. Die Hemmung der PI3K 
durch das neuartige Medikament NVP-BKM120, führte zu einer deutlich höheren 
Inhibition des Tumorwachstums im Vergleich zu RAD001 und NVP-BEZ235. Des 
Weiteren konnte gezeigt werden, dass eine duale Hemmung durch PI3K/mTOR und 
NVP-BEZ235 effektiver ist als die  RAD001 Behandlung allein. Im nächsten Schritt 
wurde die Wirkung der molekularen Medikamente in Kombination mit Doxorubicin, 
Cisplatin, 5-FU oder Irinotecan auf die Viabilität der Krebszelle  getestet. 
Interessanterweise wurde dabei deutlich, dass die Kombination von RAD001, NVP-
BEZ235 und NVP-BKM120 mit Irinotecan oder Cisplatin das Überleben insbesondere 
von Huh7-Zellen verringert. Diese Resultate sind einen Hinweis darauf, dass die 
Hemmung von mTOR eine wirksame Methode ist, um die Empfindlichkeit von 
Leberzellen gegenüber herkömmlichen Chemotherapeutika zu erhöhen. Eine 
Kombinationstherapie mit PI3K/mTOR und Chemotherapeutika könnte somit eine 
realisierbare Möglichkeit für Nicht-Zirrhose HCC Patienten mit guter Leberfunktion 
sein. 
 
Obwohl mTOR-Inhibitoren und Chemotherapeutika als therapeutische Wirkstoffe 
gegen HCC getestet werden, bleibt die Entwicklung von Resistenzen gegen diese 
Medikamente ein wichtiges klinisches Problem. Daher ist es von großem Interesse die 
wichtigsten Onkogene und entsprechende Mechanismen zu verstehen, die die 
Resistenz der Zellen im HCC steuern. Im zweiten Teil dieser Studie wurde ein in vitro 
System etabliert, um über ein genomweites shRNA-Screening, die Gene zu 
identifizieren, die die Resistenz oder Sensitivität gegenüber einer mTOR gerichteten 
Therapie vermitteln. Um die Screening-Ansätze zu validieren, wurde die Wirkung einer 
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shRNA-vermittelte Reduktion von FKBP12 auf die Anti-Tumor-Wirkung von RAD001 
analysiert. Die Phosphorylierung von P-S6 wurde durch RAD001 deutlich reduziert, 
konnte jedoch in Zellen, die mit shRNA gegen FKBP12 vorbehandelt wurden, fast 
vollständig verhindert werden. Darüber hinaus konnte ein Knockdown von FKBP12 
durch RNA-Interferenz die RAD001 induzierte Wachstumshemmung in vitro aufheben. 
Dies zeigt, dass eine shRNA-vermittelte Reduktion von funktionell wichtigen Genen 
eingesetzt werden kann, um die grundlegenden molekularen Mechanismen der 
RAD001 Sensitivität oder Resistenz zu identifizieren. 
 
Schlüsselbegrilfe: 
 
HCC – Hepatozelluläres Karzinom 
mTOR – Säuger Ziel gen für Rapamycin 
PI3K – Phophoinositol 3 Kinase 
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Introduction 
 
1.1 Hepatocellular carcinoma 
 
Hepatocellular carcinoma (HCC) is one of the most lethal, prevalent cancer and it 
represents a major health problem worldwide (Llovet et al. 2003). HCC is the fifth most 
common cancer and ranks as the third lethal cancer worldwide (Srivatanakul et al. 
1991; Szymanska et al. 2009). It is commonly associated with hepatitis B and C virus 
infection, chronic exposure to toxins, alcohol abuse and hereditary liver diseases 
(Thorgeirsson and Grisham 2002). In contrast to other cancers, its incidence increases 
annually by 1.75% in the US and in Germany. HCC incidence by hepatitis B and C 
infections (~75%), and less frequently associated with chronic exposure to toxins or 
hereditary liver diseases (El-Serag et al. 2008).The prognosis of patients with HCC is 
dismal and the mortality rates are almost the same as the incidence rates. Surgical 
resection or local ablation of the tumor provides the best results for patients with 
limited disease. Therapeutic options for patients with advanced disease are still 
sobering and even combinations of cytotoxic drugs such as doxorubicin, cisplatin and/ 
or 5-FU produce only modest anti-tumor activity. Recently, the multikinase inhibitor 
sorafenib has shown survival benefits in some patients with advanced HCC proving 
that molecular therapies can be effective in this devastating disease. These results 
have triggered the search for additional molecular agents to further expand patient 
survival. Furthermore aberrant activation various signaling pathways, both in cirrhotic 
tissue and in overt HCC has been implicated in hapatocarcinogenesis, which was 
discussed in several previous studies (Villanueva et al. 2008; Zender et al. 2010)  and 
it is well demonstrated in Figure 1. 
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Figure 1: Signalling pathways frequently dysregulated in hepatocellular carcinoma 
Pathways are clustered according to the biological process they have been mostly implicated in 
HCC development and progression, including cell proliferation/survival, differentiation, 
inflammation, oxidative stress and angiogenesis. Adapted from Zender et al., (Zender et al. 
2010) 
 
1.2 Targeted therapies in HCC – positive and negative 
predictive factors 
 
One major factor limiting the effective treatment of HCC is the heterogeneity of the 
disease with several genomic alterations; the identical treatment can produce 
remarkably different responses ranging from complete response to progressive 
disease in patients with indistinguishable tumors at the macromolecular level 
(Thorgeirsson and Grisham 2002).  
 
Currently the gold standard to prognostication is the clinicopathological staging, which 
separates patients into groups with distinct outcomes, but offers little information about 
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response to treatment in individual patients. Understanding the factors that predict the 
benefits derived from systemic therapy will be very useful for the development of a 
more personalized and thereby more effective approach to cancer treatment. 
Furthermore, treatment can be withheld from patients that are unlikely to respond, 
avoiding not only unnecessary toxicity but also costs. Finally, understanding the 
mechanisms of resistance may uncover strategies to overcome resistance. In this 
regard, K-ras is an important predictive biomarker in colon cancer: mutations are 
limited to hot spots in the gene that are easily detected. The negative predictive value 
appeared to be high, because most patients with mutated K-ras do not respond to 
EGFR inhibition. Importantly however, more recent studies (COIN, NORDIC VII) have 
challenged this observation suggesting that a rigorous validation of biomarkers is 
critically important. Another very recent example of a prognostic and predictive 
biomarker is HER2 in gastric cancer. HER2 over-expression occurs in about 20% of 
patients with gastric cancer and has not only been correlated to poor outcomes and a 
more aggressive disease, but it has also become an important positive predictive 
biomarker for identifying a small subset of patients who respond to HER2 targeting 
therapy using the fully humanized monoclonal antibody trastuzumab. 
 
1.3 The PI3K/mTOR pathway 
 
The activated PI3K/mTOR pathway plays a critical role in cell proliferation, survival and 
has only recently emerged as a pivotal contributor to HCC development. PI3K and its 
downstream molecule AKT are commonly deregulated in many human cancers 
(Figure 2) (Engelman et al. 2006). PI3K (Phosphatidylinosital-3-Kinase) pathway plays 
a role in several cellular processes and contribute to malignant phenotype (Markman 
et al. 2010). PI3Kinase pathway begins with activation of receptor tyrosine kinase 
(RTK) in presence of growth factors, and then stimulates the production of 
phosphatidylinositol 3, 4, 5-triphosphate (PIP3) from PIP2 and subsequently the 
activation of  (Phosphoinositide-Dependent kinase-1) PDK1/ AKT and mTOR. mTOR 
(mammalian target of rapamycin) is a serine/ threonine kinase that integrates 
mitogenic and nutrient signalling to regulate proliferation, cell cycle progression, 
mRNA translation, cytoskeletal organization and survival (Guertin and Sabatini 2007). 
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Interest in the regulation of mTOR has increased substantially in recent years largely 
because of an apparent link between deregulation of translation and cancer cell 
survival (Shaw and Cantley 2006). The first mTOR proteins were identified in a genetic 
screen for mutations conferring resistance to rapamycin. In a complex with FK506-
binding protein 12 (FKBP12) rapamycin binds to and inhibits mTOR. mTOR forms two 
physically and functionally distinct complexes: a rapamycin sensitive complex, 
mTORC1, and a second rapamycin insensitive complex, TORC2. The best 
characterized downstream effectors of mTOR as part of TORC1 complex are proteins 
of the 4E-BP1 family and the P S6 protein kinases, which act in parallel to control 
mRNA translation (Bjornsti and Houghton 2004). Hypophosphorylated 4E-BP1 binds 
to and inhibits the translation initiation factor eIF4E. Upon phosphorylation by mTOR, 
4E-BP1 releases eIF-4E, which binds the cap at the 5’ ends of mRNA transcripts and 
assembles with other translation initiation factors to initiate cap-dependent translation. 
The eIF-4E complex is thought to particularly enhance translation of transcripts 
possessing complex 5’-untranslated regions, which encode various growth factors, cell 
cycle regulators, survival proteins and angiogenic factors.  
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Figure 2: The PI3K/AKT/mTOR signaling pathway and associated inhibitors.  
A ligand engaged RTK binds PI3K, either directly or indirectly via adaptor molecules such as 
IRS1, removing the inhibitory action of the p85 regulatory subunit on the catalytic p110 subunit. 
The active kinase generates PIP3 at the lipid membrane. PIP3 facilitates the phosphorylation of 
AKT by PDK1, while the mTOR-rictor complex contributes a second phosphate residue to AKT. 
As the central effector of the PI3K pathway, AKT transmits signal to a host of downstream 
substrates, thus influencing a variety of key cellular functions. Pathway activity is negatively 
regulated by PTEN and the S6K-IRS1 feedback loop. Pharmacological inhibition of the pathway 
is achieved through a variety of compounds in clinical use at various points along the pathway 
that are indicated by the red line. Adapted from  Markman et al., (Markman et al. 2010). 
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1.4 mTOR inhibitors role in cancer 
 
The immunosuppressive drugs sirolimus (rapamycin), temsirolimus (CCI-779) and 
everolimus (RAD001) are currently used as pharmaceutical inhibitors of mTOR. 
 
 
 
 
Figure 3: RAD001 chemical structure 
 
 
The networks that normally signal to mTOR comprise numerous oncogenes and tumor 
suppressors. It is therefore not surprising that dysregulation of this pathway through 
genetic mutations, amplifications or loss of heterozygosity has been detected in a 
large percentage of the most common human cancers. These findings have spurred 
interest in developing and testing mTOR inhibitors to evaluate their potential as 
anticancer agents. In most mammalian cells treatment with rapamycin blocks or at 
least delays G1-cell cycle progression and increases cell death when used in 
combination with other therapeutic agents (Beuvink et al. 2005). In vivo, rapamycin 
impairs growth of primary and metastatic tumors. Inhibition of tumor growth was linked 
to a decreased production of VEGF and markedly reduced response of endothelial 
cells to stimulation by VEGF (Guba et al. 2002). The proof of principle that mTOR 
inhibitors can improve cancer patient survival has been obtained from clinical trials in 
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advanced renal carcinoma, but also in mantle cell lymphoma and endometrial cancer. 
This has started extensive preclinical and clinical programs to further evaluate mTOR 
inhibitors in nearly all major forms of cancer (Faivre et al. 2006).  
 
Although preclinical studies have shown that rapamycin and its analogous are potent 
inhibitors of tumor cell proliferation, the roles of specific down-stream pathways of 
mTOR have been poorly defined. Additionally, it is important to note that broad-based 
use of mTOR inhibitors has not been as effective as initially anticipated, although 
many trials are still underway. One reason for this might be due to the fact that multiple 
mTORC1 dependent feedback loops exist to regulate the activation of upstream 
components of the network. For instance, a loss of the upstream tumor suppressors 
TSC1 and 2 results not only in the increased levels of mTORC1 signaling but also in a 
disease with a very low malignant potential. Loss of AKT activation due to S6K-
mediated phosphorylation of IRS-1 most likely accounts for the very slow-growing 
nature of these tumors. Thus, targeting this pathway affects multiple cellular processes 
that are difficult to predict and may not only inhibit tumor development and 
progression, but can also result in exacerbation of tumor growth due to activation of 
feedback mechanisms.  
 
Consequently, major efforts have been undertaken to identify surrogate markers for 
assessing the efficacy of mTOR inhibitors and to identify those patients who would 
benefit the most from mTOR inhibition. As mTOR is ubiquitously expressed, the 
sensitivity to mTOR inhibitors cannot be predicted on the basis of its tissue-specific 
expression. Most clinical trials have investigated expression of PTEN and activation/ 
phosphorylation of AKT, mTOR and P S6K1. Based on these studies one would 
predict that patients with PTEN inactivation and/ or high levels of phosphorylated and 
active AKT, mTOR and P S6K1 display increased sensitivity to mTOR inhibitors. 
However, other studies have shown that the effect on P S6 phosphorylation does not 
reliably predict the anti-cancer effects of these drugs. Therefore additional studies 
elucidating the mechanisms behind increased or decreased sensitivity to mTOR 
inhibitors are urgently needed to identify patients who will most likely benefit from 
these drugs.  
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The activated PI3K/mTOR pathway has only recently emerged as a pivotal contributor 
to HCC development. Aberrant mTOR signaling has been identified in up to 50-60% of 
HCC cases, associated with insulin-like growth factor pathway activation, epidermal 
growth factor up-regulation, and PTEN dysregulation (Sahin et al. 2004; Villanueva et 
al. 2008). Of note, loss of PTEN appears to occur at a rate second only to p53 and is 
reduced or absent in almost half of HCC patients (Horie et al. 2004). 
 
In vitro as well as preclinical in vivo studies revealed that mTOR inhibition by 
rapamycin and its derivatives significantly reduces HCC growth and improves survival 
(Semela et al. 2007; Buitrago-Molina et al. 2009). mTOR inhibitor RAD001 specifically 
impaired cell cycle progression in non-transformed hepatocytes with DNA damage in 
vivo. Long-term treatment with RAD001 markedly delayed DNA damage-induced liver 
tumor development indicating that mTOR activation has a substantial effect on 
hepatocarcinogenesis (Buitrago-Molina et al. 2009). Recent data suggest that 
activation of AKT via mTORC2 in response to mTORC1 inhibition with rapamycin 
contributes to drug resistance (Carracedo et al. 2008). 
 
Moreover, mTOR inhibition in combination with conventional chemotherapy or VEGF 
and EGFR inhibitors has been shown to enhance the anti-neoplastic potency of the 
respective monotherapeutic drugs (Sieghart et al. 2007; Huynh et al. 2008; Piguet et 
al. 2008). Several clinical trials have therefore been initiated to evaluate the effect of 
mTOR inhibitors for the treatment of advanced HCC (Rizell et al. 2005; Rizell et al. 
2008). 
 
Although some studies have explored the mechanisms by which rapamycin exerts its 
anti-tumor effects on HCCs, studies on rapamycin resistance are lacking. Only very 
recently a panel of 13 tumorigenic and non-tumorigenic hepatic cell lines has been 
profiled for rapamycin-induced growth arrest (Jimenez et al. 2009). Rapamycin 
potently inhibited phosphorylation of P S6K in all cases, however the cell lines showed 
a wide range of sensitivity/ resistance to the growth inhibitory effects of the drug 
implying a level of complexity that present challenges to identify HCC patient that will 
respond to mTOR inhibitors. Even microarray analysis did not disclose an unifying 
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mechanism for rapamycin resistance implying a level of complexity that present 
challenges to identify HCC patient that will respond to mTOR inhibitors.  
 
1.5 PI3Kinase inhibitors in cancer 
 
Previously, wortmannin (Powis et al. 1994) and LY294002 (Vlahos et al. 1994) were 
used as a PI3K inhibitors. Wortmannin is fungal metabolite and was isolated from 
Pencillium wortmannin in 1957. LY294002 is a synthetic compound derived from 
quercetin. 
 
Both agents achieved significant growth inhibition in a broad spectrum of cancer cell 
lines especially in circumstances of excess PI3K activity. However, either Wortmannin 
or LY294002 have not progressed to clinical trials due to unfavorable pharmacokinetic 
properties, poor selectivity, cross talk inhibition of other lipid and protein kinases and 
toxicity concerns (Stein 2001).  Regardless, their use has led to a better understanding 
of the PI3K pathway and has spawned a new generation of inhibitors that overcome 
some of the failings of these compounds. Of these new drugs, NVP-BKM120 and 
NVP-BEZ235 are more potent inhibitors of PI3K. In PI3K pathway, AKT activation 
requires phosphorylation of two critical residues Thr308 and Ser473. PDK1 subunit of 
PI3K is responsible for T308 phosphorylation and PDK2 for S473 phosphorylation. 
 
1.5.1 NVP-BKM120 in cancer 
 
Orally available, NVP-BKM120 is a PI3K inhibitor obtained after an extensive 
medicinal chemistry effort to modulate the biological activity and pharmaceutical 
properties of imidazo quinoline-based compounds. Recent study explained that NVP-
BKM is a potentially useful drug to delay or prevent the development of resistance to 
Smo antagonists and may inform treatment strategies for medulloblastoma. 
Medulloblastoma is a malignant brain cancer which is characterized by mutations in 
Hedgehog (Hh) signaling pathway genes, which lead to constitutive activation of the G 
protein (heterotrimeric guanosine triphosphate–binding protein)–coupled receptor 
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Smoothened (Smo). The Smo antagonist NVP-LDE225 inhibits Hh signaling and 
induces tumor regression in animal models of medulloblastoma. However, resistance 
was exhibited by the tumors during the course of treatment. Molecular analysis of 
resistant tumors revealed an up-regulation of phosphatidylinositol 3-kinase (PI3K) 
signalling in resistant tumors, as another potential mechanism of resistance. Addition 
of the PI3K inhibitor NVP-BKM120 to the initial treatment with the Smo antagonist 
markedly delayed the development of resistance (Buonamici et al. 2010).  
 
 
 
 
Figure 4: NVP-BKM120 chemical structure 
 
 
 
1.5.2 NVP-BEZ235 in cancer 
 
Orally available, NVP-BEZ235 is a dual PI3K/mTOR inhibitor obtained after an 
extensive medicinal chemistry effort to modulate the biological activity and 
pharmaceutical properties of imidazo-quinoline scaffold based compounds. NVP-
BEZ235 effectively blocks the dysfunctional activation of the PI3K pathway in cellular 
and in vivo settings. The compound displayed disease stasis in relevant in vivo models 
of human cancer when given orally and also enhanced the antitumor activity of other 
cancer agents. NVP-BEZ235 displays all the features required for clinical development 
and has entered phase I clinical trials in cancer patients. NVP-BEZ235 compound is 
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an ATP competitive inhibitor that directly targets the PI3K and mTOR catalytic domains 
(Figure 6). NVP-BEZ235 reduces the proliferation rate and induces an important 
apoptotic response in acute myeloid leukemia (AML) cells without affecting normal 
CD34+ survival. These results clearly showed the antileukemic efficiency of the NVP-
BEZ235 compound, therefore represents a promising option for future AML therapies 
(Chapuis et al. 2010). 
 
In primary effusion lymphoma (PEL), PI3K/mTOR pathway was activated.  PELs rely 
heavily on PI3K/mTOR signaling, are dependent on autocrine and paracrine growth 
factors. NVP-BEZ235, that dually inhibits both PI3K and mTOR kinase was 
significantly more efficacious in culture and in a PEL xenograft tumor model. NVP-
BEZ235 was effective at low nanomolar concentrations and had a novel mechanism 
involving the suppression of multiple autocrine and paracrine growth factors required 
for lymphoma survival. This study showed a broad applicability for the treatment of 
cytokine-dependent tumors with PI3K/mTOR dual inhibitors (Bhatt et al. 2010). In 
another study, NVP-BEZ235 inhibited waldenstrom macroglobulinemia (WM) which 
had a constitutive activation PI3K/mTOR pathway. It was noticed that both rictor and 
raptor were inhibted by NVP-BEZ235 and thus abrogating the rictor-induced AKT 
phosphorylation. Additionally, NVP-BEZ235 targeted WM cells in the context of bone 
marrow microenvironment, leading to significant inhibition of migration, adhesion in 
vitro, and homing in vivo. Therefore, this study showed the dual targeting of the 
PI3K/mTOR pathway is a better modality of targeted therapy for tumors (Roccaro et al. 
2010). 
 
Multiple myeloma (MM) cells also showed antitumor sensitiveness towards NVP-
BEZ235 with lower concentrations. Combinations of NVP-BEZ235 with conventional 
(e.g., dexamethasone and doxorubicin) or novel (e.g., bortezomib) anti-MM agents 
showed lack of antagonism. These results strongly support the NVP-BEZ235 efficacy 
in clinical testing, alone and in combination with other agents (McMillin et al. 2009).  
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Figure 5: NVP-BEZ235 chemical structure 
 
 
 
 
 
 
 
 
 
 
Figure 6: NVP-BKM120 and NVP-BEZ235 mechanism of action 
NVP-BKM120 and NVP-BEZ235 inhibits tumor proliferation and survival by blocking the 
phosphatidylinositol-3-kinase (PI3K) pathway.  Adapted from www.novartis.org 
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1.6 Chemotherapeutic drugs in cancer 
 
Chemotherapeutic drugs are anticancer drugs that mainly disrupt the cancer cell 
growth. Chemotherapy is generally used to kill the cancer before surgery or 
sometimes after surgery to completely eliminate the cancer cells from the body. There 
are several chemotherapeutic drugs which are mainly used to treat the cancer. 
1.6.1 Doxorubicin 
 
Doxorubicin is an anthra cycline antibiotic, mainly used to treat cancer. It was isolated 
from soil bacterium Streptomyces peucetius, in 1950. Italian research company, 
Farmitalia Research Laboratory, found out the doxorubicin from soil microbes. This soil 
sample was isolated from the area of Castel del Monte, in Italy. This bacterial strain of 
Streptomyces peucetius, produced a red pigment, called as doxorubicin, that was 
found to have good activity against murine tumors. As this drug was in red colour, so it 
is called as a doxorubicin. French word for rubis, describing the color. It intercalates 
with DNA and therefore blocks the DNA replication. Based on clinical trials in 1960s, 
the drug proved to be successful in treating acute leukemia and lymphoma. However, 
it could produce fatal cardiac toxicity. In one study it was showed that, 14 patients with 
hepatocellular carcinoma were treated with adriamycin (trade name of doxorubicin) 
administered intravenously at a dose of 75 mg/m2 every 3 weeks. 11 evaluable 
patients responded to the treatment, with 3 exhibiting complete tumor regressions after 
two, three, and five courses of adriamycin respectively. The median survival of the 
evaluable patients is 8 months (range 1-13 months). The side effects encountered 
include myelosuppression, anorexia, nausea, vomiting, and alopecia. Adriamycin 
seems to be an effective agent in hepatocellular carcinoma. Further more studies were 
carried out to test efficacy of doxorubicin both by single and  combination with other 
drugs in controlling the tumor progression (Olweny et al. 1975). Combination with 
rapamycin had showed appreciable promise in treating the lymphomas in mice 
(Wendel et al. 2004). Additional study of combining doxorubicin and paclitaxel resulted 
mainly in arresting the cells in G2/M phase of the cell cycle. In vivo anti-tumor activity 
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assay also showed that the combination of the two drugs resulted in more significant 
tumor regression, compared to the single treatment(Jin et al. 2010). 
 
 
 
 
 
 
 
Figure 7: Doxorubicin chemical structure 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
1.6.2 Cisplatin 
 
Cisplatin was discovered by Dr. Rosenberg in 1965 while he was examining the effect 
of electromagnetic field on bacterial cell growth (Rosenberg et al. 1965; Rosenberg 
1985). Since the active principle that inhibited bacterial cell division was identified as 
cisplatin, he anticipated that it would also inhibit the proliferation of rapidly dividing 
cancer cells. Cisplatin was indeed demonstrated to possess antitumor activity in a 
mouse model (Rosenberg et al. 1969) and was first used in the clinical trial almost 30 
years ago. Since its approval by the Food and Drug administration in 1978, cisplatin 
continues to be one of the most effective anticancer drugs used in the treatment of 
solid tumors. 
 
Cisplatin is a platinum based drug which is used to treat many cancers. Basically, it 
intercalates with DNA and prevents DNA replication. In a mechanistic way, platinum 
binds to guanine base on DNA and leads to DNA damage, finally leading to apoptosis. 
In previous study, it was showed that S phase arrest occurred due to the cisplatin 
treatment. Endoreduplication as a result of cisplatin treatment, might be a valuable 
procedure to evaluate the risk of developing secondary leukaemia and other 
malignancies as well (Cantero et al. 2006). 
 
Cisplatin treatment had several side effects like headache, nausea, sore throat; 
Infection chances are higer and one can experience tiredness and breathlessness due 
to low number of white blood cells and red blood cells.  In one study, cisplatin was 
shown to be useful in the intra-arterial treatment of hepatocellular carcinoma with 
favourable prognostic factors in patients for whom surgical treatment is not suitable 
(Kajanti M, 1986). In a phase II study conducted in 28 previously untreated patients 
with unresectable hepatocellular carcinoma, cisplatin treatment resulted in partial 
responses lasting for > 3 months in 4 out of 26 patients evaluated, while no patient 
achieved a complete response. Out of 22 patients whose serum levels of alpha-
fetoprotein (AFP) were high (> 400 ng/ml) before treatment, 6 (27.3%) showed a > 
50% reduction in serum AFP levels after cisplatin treatment. This indicates that 
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cisplatin is an anticancer agent worthy of further testing in patients with this disease 
(Okada et al. 1993). 
 
Recently, it was showed that HCC cell lines exposed to RAD001 in combination with 
cisplatin resulted in a significant increase in the number of apoptotic cells, 
downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, 
and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. The 
suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with 
cisplatin, accompanied by a significant increase in the number of apoptotic cells in 
tumor tissues (Tam et al. 2009). In another study, by combining adenovirus harboring 
ING4 with cisplatin enhanced antitumor activity in hepatocarcinoma cells (Xie et al. 
2010). 
 
 
 
 
 
 
Figure 8: Cisplatin chemical structure 
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1.6.3 5FU (5 Fluro Uracil) 
 
5FU is a pyramidine analogue which has been in use for the past 40 years in cancer 
treatment. It acts as a thymidylate synthase inhibitor. When pyrimidine thymidine is not 
available for DNA replication, cancerous cells undergo cell death via thymidineless 
death. Chemotherapy is commonly used for the treatment of human malignancies. 
Continuous infusion of 5FU to the patients is a potentially efficacious palliative therapy 
in the management of pancreas cancer (Hansen et al. 1988).  Albeit, single 
chemotherapeutic agent is not having enough effectiveness in suppressing HCC, it 
suggested that combination of several chemotherapeutic agents may be effective 
against advanced HCC. Combination therapy with 5-fluorouracil (5-FU) and IFN-α in 
colon cancer and hepatocellular carcinoma rendered better effects than single drug 
treatments. IFN-α significantly enhanced the growth inhibitory effect of 5-FU in 
PLC/PRF/5 and delay in the progression of G0/G1 to S phase and down-regulation of 
cyclinD1 was observed (Eguchi et al. 2000). In another study it was prominent that 
HepG2 cells radiosensitivity is low, thereby combining a chemotherapeutic drug with a 
radiotherapeutic agent improves the radiosensitivity in a synergistic fashion. This 
combination is thus able to strengthen the therapeutic effect of internal radiation 
therapy in different malignancies, particularly in HCC (Chenoufi et al. 1998). 
 
 
 
Figure 9: 5FU chemical structure 
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1.6.4 Irinotecan 
 
Irinotecan is a topoisomerase 1 inhibitor, which prevents DNA from unwinding. Many 
studies proved that irinotecan and its active metabolite SN-38 are very effectively 
inhibiting the cancer cell proliferation, leading to cell death (Ueno et al. 2002). SN-38 
(active metabolite of irinotecan) led to significant decrease in cell proliferation and 
induced apoptosis in Huh7 cells and HepG2 cells. SN-38 treatment significantly 
increased the expression of p53 protein and its phosphorylation at Ser15 in the 
nucleus and apoptosis-inducing proteins Bax, caspase-9, and caspase-3, while it 
significantly decreased the antiapoptotic protein Bcl-xL in Huh7 cells. An anti-tumor 
effect of SN-38 harbors the mechanism of the mitochondria-apoptotic pathway 
inducing p53 activation and thereby is a good strategy to control HCC (Takeba et al. 
2007; Takeba et al. 2007). In another study, it was showed that the expression of P-
glycoprotein induced by short-term culture of HCC with SN-38 is associated with the 
inhibition of apoptosis via p53- mitochondrial pathway and thus p53 gene 
downregulation affects the chemosensitivity to irinotecan. Thereby, the inhibition of 
apoptosis in HCC is due to acquired resistance with SN-38 accumulation (Takeba et 
al. 2007).  
 
 
 
 
 
 
Figure 10: Irinotecan chemical structure 
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1.7 Genome wide shRNA screening using RNA interference 
 
RNA interference (RNAi) has recently emerged as a powerful tool to perform genetic 
loss-of-function studies. RNA interference mechanism facilitates loss-of-function 
genetics in mammalian cells and has been used to explore various aspects of cancer 
biology, like function of oncogenes and tumor-suppressor genes.  
 
Moreover, the availability of genome-wide libraries of shRNAs capable of stably 
repressing gene expression has enabled genetic screens for determinants of 
oncogenic transformation as well as potential therapeutic targets (Westbrook et al. 
2005; Berns et al. 2007). 
 
Libraries of DNA-based vectors encoding shRNAs capable of targeting most genes in 
the human genome have been produced, which enable forward genetic screens in 
mammalian cells. Previous studies have shown that RNAi based genetic screens can 
be highly efficient in identifying genes that control the cellular response to 
chemotherapy. Importantly, loss and gain of function screens can be carried out in a 
high throughput manner and can lead to the identification of causal factors due to the 
functional nature of the approach. Several reagents have been developed to trigger 
RNA interference and several delivery systems including Moloney virus-based, 
lentiviral and adenoviral vectors can be used for plasmid derived shRNAs (Zender et 
al. 2008).  
shRNA is a sequence of RNA that makes a tight hairpin turn which then silences gene 
expression through RNA interference. shRNA introduced through lenti/retro viral 
vectors into cells utilizes the U6 promoter present in the vector and is expressed 
constitutively. This vector is usually passed on to the daughter cells, allowing the gene 
silencing to be inherited. The shRNA hairpin structure is cleaved by the DICER, an 
endoribonuclease, into siRNA (small interefering RNA), which is then bound to the 
RNA-induced silencing complex (RISC). This complex binds to the complementary 
mRNA and cleaves the mRNAs (Figure 11).  
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shRNA screens may be particularly useful to identify genes that modulate the 
response to anti-proliferative drugs. A unique barcode of each shRNA vector can be 
used to identify the genes that confer resistance or sensitivity  (Berns et al. 2004). 
Importantly, this approach may allow the identification of unknown components of 
targeted pathways and thereby of new druggable therapeutic targets (Brummelkamp 
et al. 2006; Tyner et al. 2009). 
 
Several shRNA-based screens have been successfully performed to identify drug 
resistance genes. PTEN for example was identified to confer resistance to the HER2 
antibody trastuzumab (Herceptin). Importantly, correlation of this in vitro finding with 
the outcome of breast cancer patients revealed that patients with an activated PI3-
kinase pathway have poor prognosis after trastuzumab therapy (Berns et al. 2007).  
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Figure 11: Lentiviral delivery of shRNAs and mechanism of RNA interference in 
mammalian cells.   
(Adapted from wikipidea) 
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1.7.1 FKBP12 
 
FKBP12 is a cytosolic ubiquitously expressed protein having the 12-KDa size. It mainly 
serves as a receptor for the immunosuppressant drug. FK506 binds tightly to 
intracellular calcium release channels and to the transforming growth factor β (TGF-β) 
type I receptor.  Apart from working as a receptor for immunosuppressive drug, it also 
works as a receptor for mTOR inhibitors such as rapalogs like rapamycin, RAD001 etc. 
The schematic diagram clearly explains the link between FKBP12 action and RAD001 
treatment (Figure 12). In the case of FKBP12 silencing, RAD001 mediated mTOR 
inhibition is lost there by the downstream mTOR targets will be activated leading to cell 
proliferation and metabolism. 
 
 
 
 
 
Figure 12: Schematic representation of mTOR pathway after using RAD001 
FKBP12 come into the action in the presence of RAD001 and it forms a complex and binds to 
mTOR, thereby it prevents the mTOR phosphorylation and leads to dephosphorylation of 4E-
BP1 and P70S6K. Eventually it drives the inhibition of cell proliferation and metabolism. 
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2 Aim of the study 
 
The aim of the study was to determine the role of PI3K/mTOR inhibitors alone and in 
combination with chemotherapeutic drugs in HCC treatment and also to establish an in 
vitro system, to perform the genome wide shRNA screening in order to identify genes 
that mediate resistance or sensitivity to mTOR directed therapies. 
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3 Materials and Methods 
 
3.1 Cell lines  
 
3.1.1 Huh7 cell line 
 
Huh7, is a well differentiated human hepatocellular carcinoma cell line that was 
originally taken from a liver tumor in a 57-year-old Japanese male in 1982, produces 
high levels of alpha-fetoprotein and having a point mutation of p53 (codon 220).  
 
3.1.2 HepG2 cell line:  
HepG2 is a hepatocellular carcinoma cell line which was derived from the liver tissue 
of a 15 year old Caucasian American male with a well differentiated hepatocellular 
carcinoma. These cells are epithelial in morphology. This cell line has been proven to 
be a useful model of the human liver cell as there is high proportion of liver-specific 
proteins identified in the medium, for which there are antisera  commercially available 
(Liu et al. 1985). Thus, the studies encourage a wider application of this HepG2 cell 
line to biological problems that relate specifically to the role of the liver (Javitt 1990).  
 
3.1.3 Pheonix cells 
 
The Phoenix Retroviral Expression System offers the most time-tested method for 
producing infectious, replication-incompetent retrovirus that can efficiently transfer 
genes into a variety of mammalian cell types in vitro or in vivo. It is based on Moloney 
Murine Leukemia Virus (MMULV) and allows for delivery of genes to most dividing 
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mammalian cell types, including many difficult-to-transfect cells. The main features of 
Pheonix cells are, fast and high-titre virus production, production of helper free 
ecotropic and amphotropic retroviruses and are highly transfectable with either calcium 
phosphate mediated transfection or lipid-based transfection protocols. 
 
3.1.4 HEK 293T cells  
 
HEK 293 (Human Embryonic Kidney) T is a derivative of 293 cells that stably express 
the large T-antigen of SV40.  Plasmids containing the SV40 origin are replicated to a 
copy number of between 400 - 1000 plasmids per cell within 293T, and therefore 
express at a higher level.  The HEK293T cell line is for use in facilitating optimal 
lentivirus production.  
 
3.1.5 Culture medium 
 
Except HepG2 all cells were maintained in DMEM Glutamax medium (GIBCO) 
supplemented with 10% fetal calf serum (PAA) and penicillin 100 U\ml, streptomycin 
100µg\ml antibiotics (Biochrom AG) at 37°C in 5% CO2 in humidified chamber but 
HepG2 cells were maintained in RPMI Glutamax medium (GIBCO).  
 
3.2 Nude mice 
 
Nude mouse is a strain with a genetic mutation which leads to the lack of thymus. The 
genetic basis of the nude mouse mutation is a disruption of the FOXN1 gene resulting 
in an inhibited immune system due to a greatly reduced number of T cells. The 
phenotype of the mouse is a lack of body hair, which gives it as the "nude" nickname. 
The nude mouse is valuable to research because it can receive many different types 
of tissue and tumor grafts, as it mounts no rejection response. Therefore, nude mouse 
entry came into cancer research field with major importance. 
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Nude male mice (nu\nu) of 8-10 weeks old were used as an in vivo model of this study 
and purchased from Animal Centre of Hannover Medical School. Mice were housed in 
rooms with constant temperature, humidity and 12hrs light/dark cycles. Food and 
water were available ad libitum. Animal care and experiments were all in accordance 
with the guidelines of the department of animal care at Hannover Medical School, 
Hannover, Germany. 
 
3.3 Chemotherapeutic drugs 
 
Chemotherapeutic drugs Doxorubicin (Sigma), Cisplatin, 5FU (5Fluro Uracil) and 
Irinotecan were supplied by Hannover Medical School therapeutic drug centre. 
 
3.4 PI3K/mTOR inhibitors 
3.4.1 RAD001 (Everolimus) 
 
RAD001, an orally available drug and is a rapamycin analogue, was provided by 
Novartis Pharma AG. RAD001 was formulated at 2% (w/v) in a micro emulsion vehicle, 
which was diluted in DMSO for in vitro studies and in water for in vivo studies. Animals 
were treated with 10mg/Kg body weight.  
3.4.2 NVP-BKM120 
 
NVP-BKM120 is an orally available drug and was provided by Novartis Pharma AG. 
For in vitro studies, it was diluted in DMSO and for in vivo studies it was dissolved in 1 
volume of NMP (1-methyl-2-pyrrolidone: #Fluka) and 9 volumes of PEG300 (Fluka). 
Animals were treated with this solution in the next 30 minutes/1hr with 60mg/Kg body 
weight in a volume of 7.5ml/Kg bodyweight.  
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3.4.3 NVP-BEZ 235 
 
NVP-BEZ235 is an orally available drug and was provided by Novartis Pharma AG. 
For in vitro studies, it was diluted in DMSO  and for in vivo studies it was dissolved in 1 
volume of NMP (1-methyl-2-pyrrolidone #Fluka) and 9 volumes of PEG300 (Fluka). 
Animals were treated with this solution in the next 30 minutes/1hr with 45mg/Kg body 
weight in a volume of 7.5ml/Kg bodyweight.  
 
3.5 MTT assay 
 
HCC cells were seeded in 96 well plates at a density of 1X104 cells –Huh7 and 2X104 
cells–HepG2 per well (200µl) and were grown for 16 hrs. Then the cells were treated 
with respective PI3K/mTOR inhibitors and chemotherapeutic drugs alone and 
combination for 48hrs. After treatment period, 20µl of MTT solution (Promega) was 
added to each well and absorbance was measured at 490nm.  
 
3.6 Crystal violet staining 
 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well (200µl) 
and were grown for 16 hrs. Then the cells were treated with respective PI3K/mTOR 
inhibitors and chemotherapeutic drugs alone and combination for 48hrs. Next, wash 
the cells with 200ul of PBS, fix the cells with 1% Glutaraldehyde (PAA) solution 100ul 
per well for 20 min at RT.  A fresh stock of 25% glutaraldehyde was made each time. 
Staining of the cells was done with 0.02% crystal violet (made up in 10%EtOH) 
(Sigma) by adding 100ul per well at RT for 30 min.  Cells were washed with 200ul of 
sterile water 2 X 15 minutes at room temperature. Then crystal violet was dissolved 
with 180ul of 70% ethanol per well. Keep it on shaker for 3-4 hrs at 400rpm. Make 
dilutions with sterile water and measure the absorbance at 590 nm. 
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3.7 Immunoblotting experiments 
 
For In vitro studies, cells were seeded at a density of 1.5x106 cells in 10cm dish and 
incubated for 16hrs at 37°C with 5% CO2. Cells were treated with RAD001, NVP-
BKM120, NVP-BEZ235, Doxorubicin, Cisplatin, 5FU, Irinotecan alone and in 
combination with each other for 48hrs. Cells were then lysed in 1x lysis buffer (Cell 
Signalling) containing 1X protease Inhibitor mixture (Roche, Mannheim, Germany), 
centrifuged for 10min at 15000 rpm. Then supernatant was collected.  
 
For In vivo studies, tumour tissue was lysed in 1x lysis buffer (Cell Signalling) 
containing 1X protease Inhibitor mixture (Roche, Mannheim, Germany), centrifuged for 
10min at 15000 rpm. Then supernatant was collected.  Protein quantification was done 
from the supernatant by adding Bio-Rad Protein Assay Dye Reagent (80µl of diluted 
protein extract/distilled water to 20µl reagent) and measured OD at 595nm in a 
spectrophotometer. Then, 100µg protein extracts containing an electrophoresis 
sample buffer (4x ESB: 0,5M Tris Base, 40% glycerol, 12% SDS, 0,08% w/v 
bromophenol blue, 20% β-mercaptoethanol) were resolved in SDS-PAGE with 20mA 
and transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA) 
using a western transfer apparatus (Bio-Rad Mini-Protean) with a transfer buffer 
(25mM Tris base, pH 8.3, 192mM glycine) for 1h at 100V. After blotting, membranes 
were blocked with 5% dry milk in TBS-Tween (50mM Tris base, pH 7.5, 150mM NaCl, 
0.1% Tween) for 30min at RT. Then membranes were incubated with the primary 
antibody solution (5% dry milk in TBS-Tween for unphosphorylated antibodies and 5% 
BSA in TBS-Tween for phosphorylated antibodies) overnight at 4°C. Afterwards, 
membranes were washed with TBS-Tween and incubated with the respective 
secondary antibody (5% dry milk in TBS-Tween) for 1h at RT and washed with TBS 
Tween. Detection of protein band was done using the chemiluminescence kit (Western 
Lightning®–ECL, Enhanced Chemiluminescence Substrate, and Perkin Elmer) and 
enhanced chemiluminescence films (HyperfilmTM ECL, Amersham/GE Healthcare). 
Ponceau red staining was performed with each membrane to demonstrate equal 
protein loading of the samples. 
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3.8 Primary Antibodies 
 
Name      Company 
4E-BP1      Cell Signalling 
c-jun       Cell Signalling 
cyclin A      Santa Cruz Biotechnologies 
cyclin B1      Santa Cruz Biotechnologies 
cyclin D1      Santa Cruz Biotechnologies 
Phospho-Akt (Ser473)    Cell Signalling 
Phospho-S6 ribosomal protein 
 (Ser240/244)      Cell Signalling 
p21       Santa Cruz Biotechnologies  
p38       Cell Signaling 
p-ERK      Cell Signalling 
 
 
 
 
 
 
3.9 Secondary Antibodies 
 
Name      Company 
Goat anti-mouse IgG-HRP   Santa Cruz Biotechnologies 
Goat anti-rabbit IgG-HRP    Santa Cruz Biotechnologies 
Donkey anti-goat IgG-HRP    Santa Cruz Biotechnologies 
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3.10 FACS experiments  
 
3.10.1 Cell cycle analysis with PI (Propidium Iodide) 
 
Huh7 cells were grown to 100% confluency in 6cm dish and allowed to grow 24 hrs 
extra to make tight contact inhibition. Then cells were splitted and seeded into new 
plates where cells are treated with all PI3K/mTOR inhibitors and chemotherapeutic 
drugs for 24hrs. Afterwards, cells were trypsinized and fixed in 70-75% ethanol. Then 
cells are centrifuged and suspended in 1ml solution containing 250µg of RNase 
(Sigma) and 20µg of propidim iodide (Sigma) with 1x PBS. Cells were kept at 37°C for 
30 min. Cells were acquired with flow-cytometer (FACS Caliber, BD) and data was 
analysed with FlowJo software.  
3.10.2 Apoptosis ananlysis with AnnexinV/PI staining. 
 
Huh7 cells were seeded in 6 well plates at a density of 0.25X106 cells per well and 
allowed to grow for 16hrs. Then cells were treated with all PI3K/mTOR inhibitors and 
chemotherapeutic drugs for 48hrs. Afterwards, supernatant was collected and rest 
adherent cells were trypsinized centrifuged along with supernatant cells at 1200rpm for 
5min at room temperature. Then pellet was washed with 1xPBS and centifuged again 
at 1200rpm for 5min at room temperature. Rest of the protocol was performed 
according to manufacturer’s protocol (BD). Cells were acquired with flow-cytometer 
(FACS Calibur, BD) and data was analysed with FlowJo software.  
 
3.11 In vivo antitumor activity 
 
Eight to ten week old male nude mice (nu\nu) were purchased from Animal Centre of 
Hannover Medical School and maintained under aseptic conditions as per MHH 
animal Care Centre. Healthy growing 9x106 Huh7 cells were implanted into mice by 
subcutaneous injection in right or left rear dorsal flank region. Treatment was started 
when mice developed tumours at size of 5mm in any direction, using the higher 
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concentration of each molecular target which was recommended by manufacturer. 
Mice were treated by oral gavage (RAD001 20mg/kg, NVP-BKM 60mg/kg and NVP-
BEZ 45mg/kg body weight) and cisplatin (i.p, 3mg/kg body weight) alone and 
combination of molecular target inhibitors with cisplatin. Mice were monitored daily. 
After 2 weeks of treatment, mice were sacrificed; size of the tumour was measured by 
calliper, body weight was measured, 0.5ml of blood from the orbital sinus or portal vein 
was collected and tumours were harvested. Tumour volume was calculated using the 
following formula.  
 
Tumour volume V= [(π/6) x (Length) x (Width²)]  
 
3.12 Mouse blood collection 
 
Mice blood was taken from the orbital sinus using a glass capillary tube or from portal 
vein and collected in tubes containing heparin (Li-heparin LH/1.3 ml, Sarstedt) and 
processed as per manufacturer instructions.  
 
3.13 Mouse tumour collection 
 
After sacrificing the mouse, tumour was separarted from the mouse and got rid of the 
skin and divided into four pieces. First and second pieces were frozen in liquid 
nitrogen and kept at -80°C for DNA, RNA and protein analysis. Third piece of the 
tumour was fixed in formalin and embedded in paraffin. The fourth piece was 
embedded in OCT and kept at -20°C. 
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3.14 Histology 
3.14.1 Hematoxylin and Eosin (H&E) staining 
 
Paraffinized tissue was sectioned into 5µm size and then deparaffinized in xylene and 
rehydrated in 3 different concentrations of ethanol solutions. Next slides were washed 
with distilled water and nucleus was stained with hematoxylin solution (Merck) for 15-
30sec. Sections were washed with warm tap water to allow the stain to develop. After 
rinsing with distilled water, cytoplasm was stained with acidified eosin solution (Sigma-
Aldrich) for 2min. Sections were rehydrated, cleared and mounted with a xylene-based 
mounting medium. 
 
3.14.2 Ki67 staining 
 
Proliferation of cancer cells (Huh7) was determined by the presence of Ki67 cell cycle-
related nuclear protein expressed in all phases of the cell cycle. Tissue sections of 
5µm were deparaffinized and rehydrated. Then washed with distilled water and 
antigen unmasking was performed by incubating sections in EDTA retrieval buffer 
(1mM EDTA,10mM Tris Base, 0.05% Tween) in a water bath at 95°C for 45min. After 
cooling down and washing with distiller water, endogenous peroxidases were blocked 
with 3% H2O2 for 10min. Endogenous avidin/biotin were blocked with Avidin/Biotin 
solutions (Avidin/Biotin Blocking Kit, Vector laboratories) for 15min each at RT. To 
reduce unspecific binding of antibodies, sections were blocked with 5% normal goat 
serum for 1h at RT. Then, sections were incubated with anti-Ki67 antibody (1:1000, 
2% normal goat serum, Vector laboratories) overnight at 4°C. The next day, sections 
were incubated with broad-spectrum plus antibody (Vector laboratories) for 30min at 
RT. After washing, sections were incubated with HRP-Streptavidin Plus (Vector 
laboratories) for 30min at RT. Then, detection was done by adding AEC solution 
(Vector laboratories) until the desired stain intensity developed. Sections were 
counterstained with hematoxylin and mounted with a water-based mounting media 
(Vector laboratories). 
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3.14.3 pHis3 staining 
 
Proliferation of cancer cells (Huh7) was determined by the presence of pHis3 cell 
cycle-related nuclear protein expressed in cell cycle. Tissue sections of 5µm were 
deparaffinized and rehydrated. Then washed with distilled water and antigen 
unmasking was performed by incubating sections in EDTA retrieval buffer (1mM 
EDTA,10mM Tris Base, 0.05% Tween) in a water bath at 95°C for 15min. After cooling 
down and washing with distiller water, endogenous peroxidases were blocked with 3% 
H2O2 for 10min. To reduce unspecific binding of antibodies, sections were blocked with 
5% normal horse serum for 1h at RT. Then, sections were incubated with anti-pHis3 
antibody (1:100, 5% normal horse serum, cell signalling #9701) overnight at 4°C. The 
next day, sectiones were washed and incubated with secondary antibody (1:100, goat 
anti-rabbit, Invitrogen) for 30 min at room temperature. After washing, sections were 
incubated with HRP-Streptavidin Plus (Vector laboratories) for 30min at RT. Then, 
detection was done by adding AEC solution (Vector laboratories) until the desired stain 
intensity developed. Sections were counterstained with hematoxylin and mounted with 
a water-based mounting media (Vector laboratories). 
 
3.14.4 TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay 
 
Detection of DNA strand breaks in apoptotic cells was confirmed with an in situ cell 
death detection kit (Roche). Five micrometer sections were deparaffinazed and 
rehydrated. Then washed with distilled water, endogenous peroxidases were blocked 
with 3% H2O2 for 10min. Antigens were unmasked by cooking sections in a 
microwave for 15min using citric acid retrieval buffer (10mM Tris Base, 0.05% Tween). 
Tissue permeabilization was done by incubating sections in a 20µg/ml proteinase K 
solution. Then, sections were fixed with 4% paraformaldehyde for 1h. After a second 
permeabilization with 0.1% Triton/0.1% sodium citrate, TUNEL analysis was performed 
by a fluorescein detection system, using reagents from a Roche kit. Sections were 
mounted with a DAPI-containing medium. Positive cells were counted using 
microscope.  
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3.14.5 CD31 and αSMA staining 
 
Double staining for CD31 (green) and α-SMA (red) of cryosectioned tumor samples 
treated either with RAD001 10mg\Kg, NVP-BKM120 60mg\kg and NVP-BEZ235 
45mg\Kg body weight on every day for 2 weeks. CD31-positive tumor vessels are 
partially covered by α-SMA-positive pericytes (arrows) and contain α-SMA-positive 
fibrotic areas (arrow heads). This experiment was performed as per Skuli N 2009.  
	  
3.15 shRNA oligos for FKBP12 gene 
 
shRNAs were designed against FKBP12 gene and each number denotes the position 
of designing shRNA on FKBP12 gene. 
 
791 
TGCTGTTGACAGTGAGCGCTTCTATGTAGTTTATAAATTATAGTGAAGCCACAGATGTATAA
TTTATAAACTACATAGAAATGCCTACTGCCTCGGA 
 
764 
TGCTGTTGACAGTGAGCGAATGGAGATGGCAGCTGTTTAATAGTGAAGCCACAGATGTAT
TAAACAGCTGCCATCTCCATGTGCCTACTGCCTCGGA 
 
740 
TGCTGTTGACAGTGAGCGAATGTGTATGTTCCCAGTTCAATAGTGAAGCCACAGATGTATT
GAACTGGGAACATACACATGTGCCTACTGCCTCGGA 
 
689 
TGCTGTTGACAGTGAGCGCTAGTGTATGCTTTGAATGTAATAGTGAAGCCACAGATGTATT
ACATTCAAAGCATACACTAATGCCTACTGCCTCGGA 
 
472 
TGCT 
GTTGACAGTGAGCGATTCGATGTGGAGCTTCTAAAATAGTGAAGCCACAGATGTATTTTAG
AAGCTCCACATCGAAGTGCCTACTGCCTCGGA 
 
262 
TGCTGTTGACAGTGAGCGAATGCTTGAAGATGGAAAGAAATAGTGAAGCCACAGATGTATT
TCTTTCCATCTTCAAGCATCTGCCTACTGCCTCGGA 
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3.16 Amplification and purification of shRNA oligos 
 
shRNAs are amplified by below protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR Program 
Initial denaturation 94°C 5 min 
             Cycle start 
Denaturation 94°C 20 sec 
Annealing 52°C 20 sec 
Elongation 68°C 25 sec 
                Cycle end 
Final elongation 68°C 5 min 
End 4°C ∞ 
 Total volume 
50µl  
End concentration 
Template (5ng/ µl) 2µl 10ng 
Water 37µl - 
10x PCR buffer 5µl 1x 
50mM MgSO4 1µl 1mM 
10mM each 1.5µl 0.3mM each 
5’ miR-Xho 0,1µM 1.5µl 3nM 
3’ miR-Eco 1.5µl 3nM 
Pfx DNA Pol( 
Invitrogen #11708-
013 
0.5µl 1.25 Units 
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After amplification PCR products were confirmed on 2% agarose gel (Invitrogen) and 
then purified with PCR purification columns (Qiagen) according to the manufactures 
protocol. 
 
3.17 Restriction digestion of amplified products (inserts) and 
vector MLP (Moloney murine leukemia vector with puromycin 
selection) 
Amplified products were subjected to restriction digestion.  
 
Insert 
 60µl total 
Cleaned up template 
(0,2 – 1µg) 
50µl 
Buffer 4 6µl 
100µg/ml BSA 0.6µl 
XhoI (NEB #R0146S) 1µl 
Water 1.5µl 
 
EcoRI (NEB #R311S) 1.0µl 
2 hr restriction at 37°C 
 
 
Vector 
 30µl total 
vector 10µl 
Buffer 4 3µl 
100µg/ml BSA 0.3µl 
XhoI (NEB #R0146S) 2.5µl 
water 11.7µl 
 
EcoRI (NEB #R311S) 2.5µl 
2 hr restriction at 37°C 
 
 
 52 
3.18 Ligation and clonning 
 
After restriction digestion, vector was treated with Cip Phosphatase (NEB #M0290S) 
and incubates for 1.5 hr at 37°C. Then vector was purified with PCR purification 
columns (Qiagen) according to the manufactures protocol.   
 
Ligation 
 Total volume 20µl 
Restricted vector 200ng 
Restricted insert 30ng 
Elution Buffer (from MN 
Kit) 
5µl 
T4 Ligase Buffer (Rapid 
kit) 
10µl 
T4 DNA Ligase 1µl 
1hr at Room temperature 
 
 
After ligation, 5µl ligation mixture was added to prechilled 50µl DH5α (E. coli) 
competent cells and kept on ice for 30 min. Then heat shock was performed at 42°C   
for 30 seconds. Then kept on ice for 10 min and added 500µl of LB medium and plated 
250µl on LB agar ampicillin50 plate (50µg/ml medium). 
 
 
LB medium 1000 ml 
NaCl (Sigma) 5g 
Trypton (Fluka) 10g 
Yeast extract (Sigma) 5g 
water 1000ml 
Autoclaving 
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LB plates (500ml) 
NaCl (Sigma) 2.5g 
Trypton (Fluka) 5g 
Yeast extract (Sigma) 2.5g 
water 500ml 
Agar 5g 
Autoclave, cool down to warm temperature and 
add antibiotics 
 
 
 
3.19 Plasmid isolation, restriction digestion and sequencing 
 
Four colonies were picked from each plate and inoculated into LB amp100 medium. 
Incubated the culture overnight and plasmid isolation was performed according to 
manufatureer kit protocol (Qigen). Restriction digestion was performed using EcoR1 
and Xho1 enzymes inorder to confirm the clones.  
 
Restiction digestion 
 Total volume 20µl 
DNA 5µl 
Buffer 4 2µl 
100µg/ml BSA 0.2µl 
XhoI (NEB #R0146S) 0.5µl 
water 11.8µl 
 
EcoRI (NEB #R311S) 0.5µl 
2 hrs restriction at 37°C 
 
Correct clones were sequenced using mir30 primers. After confirmation of correct 
clone with sequencing, again transformation was performed with correct clone and 
midiprep (Qiagen) was carried out to get enough amount of plasmid DNA. 
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3.20 Preparation of large amount of helper plasmid DNA for 
retroviral and lentiviral transfection 
 
Helper plasmid DNAs were transformed into DH5α competent cells (which was 
explained in previous experiments) and midi prep was performed according to 
manufacturer’s protocol (Qiagen). 
 
3.21 Retroviral transfection 
 
Pheonix (packaging cells) cells were seeded in 6cm Petri dish (2 plates) at a density of 
2X106 cells and were grown for 16 hrs.  
 
For each plate: 
 
Solution A: plasmid DNA 10µg, helper DNA 5 µg, 31.25µl from 2M CaCl2 (Fluka) and 
makeup the volume with sterile water to 250µl. 
 
Solution B: 250µl of 2x HBS - 280nM Nacl (Sigma), 50mM HEPES (sigma), 1.5mN 
Na2HPO4 (Fluka), 12mM glucose (Sigma) and 10mM KCl (Roth) with pH 7. 
 
Mix drop wise solution A to solution B. Use a pipette aid as a means to blow bubbles 
through solution B. Use a Pasteur pipette for drop by drop adding solution A to solution 
B while the pipette aid blows bubbles. Then leave the mixture at room temperature for 
15 min. In the mean time remove the growth medium from the packaging cells and 
replace with 3.5ml of freshly made chloroquine 25mM (Sigma) containing DMEM 
medium. Add the mixture to the cells and leave for 10-12 hrs. Change the media after 
12 hrs, and collect the virus every 24 hrs for 3 days. Virus can be stored in 4 degrees 
for up to one week. Virus was filtered through 0.45µm filter and polybrene 8µg/ml 
(Sigma) was added and the mixture was added to target cells (Huh7) with 20% 
confluency. Huh7 cells were transduced twice a day with 4ml virus for 4hrs and again 
4ml of virus for 4hrs. Then remove the virus and replace with fresh DMEM medium to 
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regenerate the cells for over night. This mode of treatment was performed for 3 days. 
Then cells were selected under puromycin selection with 10µg/ml. 
 
3.22 GFP enrichment assay 
 
Cell population was cultured as 1:1000 ratios of FKBP12 silenced and normal Huh7 
cells. These cells were subjected to RAD001 treatment for 3 days, 5 days and 10 
days.  GFP population was acquired by FACS and analysed by flowjo software.  
 
3.23 Electroporation of shRNA pools  
 
 
2µg of plasmid DNA was taken from each pool (contains 1000 shRNAs), and a total of 
5 pools were mixed. From the mixture, 1µl was taken and added to 20µl of 
elecltrocompetent cells (DH10 beta mega invitogen). This comlete mixture was 
transferred into a cuvette and subjected to 2kv and 200 pulse controller (Bio rad gene 
pulser cuvette. 0,1cm electrode). Then 1ml recovery medium was added to the mixture 
and incubated at 37° C for 40 minutes. 1µl from this mixture was added to 1ml LB 
medium (1:1000). Rest of the mixture was spreaded on to two ampicillin 50 
petridishes. In order to confirm the transformation efficiency, 50µl was taken from the 
diluted one (1:1000) and was spreaded on to a new petridish. This is to confirm the 
transformation of all hairpins by counting the colonies. Theoretically, 1ml main stock 
contains 5X106 colonies and the diluted medium (1:1000) contains 5X103 colonies.  
Therefore 50µl of the culture should theoretically give rise to 250 colonies. When 
colonies were between 200-250, experiment was continued further. All colonies were 
collected by scraper and added to 40 ml LB amp50 medium and were incubated at 
37°C for 8hrs on a shaker and then transferred to 400ml culture and incubated 
overnight at 37°C on an orbital shaker at 220rpm. Culture was harvested and plasmid 
DNA isolation was carried out by Qiagen maxiprep kit. 
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3.24 lentiviral transfection 
 
293T (packaging cells) cells were seeded in 10cm Petri dish at a density of 2X106 cells 
and were grown for a 70% confluency.  
 
For one plate: 
 
Solution A:  Plasmid DNA 20µg, pMDLg 10µg, pRSV10µg, pMD2G-10ug and 62.5µl 
from 2M CaCl2 (Fluka) and makeup the volume with sterile water to 500µl. 
 
Solution B: 500µl of 2x HBS - 280nM Nacl (Sigma), 50mM HEPES (sigma), 1.5mN 
Na2HPO4 (Fluka), 12mM glucose (Sigma) and 10mM KCl (Roth) with pH 7. 
 
Mix drop wise solution A to solution B. Use a pipette aid as a means to blow bubbles 
through solution B. Use a Pasteur pipette for drop by drop adding solution A to solution 
B while the pipette aid blows bubbles. Then leave the mixture at room temperature for 
15 min. In the mean time remove the growth medium from the packaging cells and 
replace with 9ml of freshly made chloroquine 25mM (Sigma) containing DMEM 
medium. Add the mixture to the cells and leave for 10-12 hrs. Change the media after 
12 hrs, and collect the virus every 24 hrs for 3 days. Virus can be stored in 4 degrees 
up to one week. Huh7 cells which were seeded at a density of 2.75X106 cells in 25cm2 
T flask and allowed to grow for overnight. Virus was filtered through 0.45µm filter and 
polybrene 8µg/ml (Sigma) was added and then, cells were transduced with virus to 
estimate 10-15% MOI (Multiplicity of Infection).  After 24hrs of transduction, cells were 
trypsinized and cells were acquired with flow-cytometer (FACS Calibur, BD) and data 
was analysed with FlowJo software. As transduced cells express GFP, it was easy to 
find out 10-15% MOI. Virus was filtered through 0.45µm filter and polybrene 8µg/ml 
(Sigma) was added and put it on 20X106 target cells (Huh7) cells which are in 175cm2 
T flask. After 24hrs of transduction, Huh7 cells were regenerated with fresh DMEM 
medium for 24hrs. Then cells were selected under puromycin selection. Selected cells 
are subjected to RAD001 and Placebo treatment for 10 days with one splitting on 5th 
day and genomic DNA was isolated (pure gene kit, Qiagen) 
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3.25 Statistical analysis 
 
Data was represented as the mean ± standard deviation. Two-way analysis of 
variance or Student t-test was measured to determine the significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
4. Results 
 
4.1: Therapeutic approaches for Hepatocellular Carcinoma 
using PI3K/mTOR inhibitors and combination with cytotoxic 
drugs.	  
 
4.1.1: PI3K/mTOR molecular target inhibitors have efficient 
inhibition on Huh7 cell proliferation  
 
In order to find out the effect of PI3K/mTOR molecular target inhibitors – RAD001, 
NVP-BKM120 and NVP-BEZ235 on cell viability and also 50% inhibitory concentration 
(IC50), MTT colorimetric assay was performed in Huh7 cells. The cells were treated 
with the drugs for 48hrs. RAD001 showed cytostatic effect on cell proliferation from 
10nM to higher concentrations (Figure 13) and an IC50 concentration of 50nM was 
used for further studies. NVP-BKM120 treatment was efficient in inhibiting the cell 
proliferation by dose dependent manner (Figure 14) and an IC50 concentration of 
1000nM was used for further studies. NVP-BEZ235 had a very sensitive effect on 
Huh7 cells lines even at lower concentration (Figure 15) compared to NVP-BKM120 
and an IC50 concentration of 10nM was used for further studies. 
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Figure 13: Effect of mTOR inhibitor (RAD001) on cell proliferation of Huh7 cell line 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of RAD001 for 48hrs and 
proliferation was measured by MTT assay. **P<0.01 value represents the treated vs DMSO 
values. 
 
 
Figure 14: Effect of PI3K inhibitor (NVP-BKM120) on cell proliferation of Huh7 cell line 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of (NVP-BKM120) for 
48hrs and proliferation was measured by MTT assay. **P<0.01 value represents the treated 
(represented with line) vs DMSO values. 
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Figure 15: Effect of dual PI3K and mTOR inhibitor (NVP-BEZ235) on cell proliferation of 
Huh7 cell line 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of NVP-BEZ235 for 48hrs 
and proliferation was measured by MTT assay. **P<0.01 value represents the treated vs 
DMSO values 
 
4.1.2: mTOR inhibitor RAD001 has efficient inhibition on HepG2 cell 
proliferation 
 
In order to find out the effect of mTOR inhibitor– RAD001 on cell viability and also 50% 
inhibitory concentration (IC50), MTT colorimetric assay was performed in another 
hepatocellular carcinoma cell line, HepG2. After 48hrs treatment with RAD001, HepG2 
cells showed approximately 35µM of IC50 concentration   (Figure 16). 
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Figure 16: Effect of mTOR inhibitor (RAD001) on cell proliferation of HepG2 cell line 
HepG2 cells were seeded in 96 well plates at a density of 2X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of RAD001 for 48hrs and 
proliferation was measured by MTT assay. **P<0.01 value represents the treated (represented 
with line) vs DMSO values. 
 
4.1.3 Chemotherapeutic drugs have efficient inhibition on Huh7 cell 
proliferation 
 
For chemotherapeutic drugs (Doxorubicin, Cisplatin, 5FU and Irinotecan) the dose 
dependency effect on cell proliferation and IC50 concentartion were determined by 
using MTT assay. The results had shown a dose dependent growth inhibition in Huh7 
cells after 48hrs treatment for the respective drugs (Figure 17, 18, 19 and 20). Based 
on these results, we determined the IC50 concentration for each drug for further studies 
as follows, doxorubicin – 170nM, cisplatin - 8µM, 5FU – 10µM and irinotecan - 50µM 
concentrations. In addition to MTT assays to measure cell proliferation, we also used 
crystal violet staining assay using IC50 concentration of doxorubicin, cisplatin, 5FU and 
irinotecan. The results from this assay clearly supported the data from MTT assay 
(Figure 21).  
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Figure 17: Effect of doxorubicin on cell proliferation of Huh7 cell line 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of doxorubicin for 48hrs 
and proliferation was measured by MTT assay.  t-test value was P<0.01 between the treated vs 
DMSO values.  
 
 
 
Figure 18: Effect of cisplatin on cell proliferation of Huh7 cell line 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of cisplatin for 48hrs and 
proliferation was measured by MTT assay. T-test value was P<0.01 between the treated vs 
NaCl values. 
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Figure 19: Effect of 5FU on cell proliferation of Huh7 cell line 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of 5FU for 48hrs and 
proliferation was measured by MTT assay. T-test value was P<0.01 between the treated vs 
NaCl values.  
 
 
 
 
 
Figure 20: Effect of irinotecan on cell proliferation of Huh7 cell line 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated concentrations of Irinotecan for 48hrs and 
proliferation was measured by MTT assay. T-test value was P<0.01 between the treated 
(20µM-100µM) vs NaCl values. 
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Figure 21: Assessment of chemotherapeutic drugs efficacy on cell proliferation of Huh7 
cell line by crystal violet (CV) staining method. 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with indicated chemotherapeutic drugs with IC50 
concentrations for 48hrs and proliferation was measured by CV staining method. t-test value 
was P<0.01 between the treated vs DMSO/NaCl values. 
4.1.4: PI3K/mTOR molecular target inhibitors treatment resulted in 
the inhibition of respective signalling cascades in Huh7 cells 
 
To assess the molecular mechanism of these PI3K/mTOR inhibitors in Huh7 cells, 
investigation of well known downstream mTOR targets, 4E-BP1 and P-S6 ribosomal 
proteins, were analzyed.  Additionally, phosphorylation status of AKT, as an upstream 
target of mTOR was analzyed. RAD001 down regulated the expression of the P-S6 
ribosomal protein completely and partially dephosphorylated 4E-BP1 upon mTOR 
inhibition. Contrary, phosphorylation of AKT was slightly induced. NVP-BKM120 
treatment downregulated the P-S6 ribosomal protein, partially dephosphorylated 4E-
BP1 and significantly reduced phosphorylation of AKT. Similarly to RAD001, NVP-
BEZ235 downregulated the P-S6 ribosomal protein expression, partially 
dephosphorylated 4E-BP1 and slightly induced phosphorylation of AKT (Figure 22).  
However, AKT phosphorylation was repressed with higher concentration of NVP-
BEZ235 (Figure 23). 
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Figure 22: Analysis of P-S6R, 4E-BP1 and pAKT expression in Huh7 cells after treating 
with RAD001, NVP-BKM120, NVP-BEZ235 alone and in combination. 
Analysis of the expression of P-S6R, 4E-BP1 and pAKT for 48hrs was performed with western 
blotting. β actin was used as an internal loading control.  
 
 
 
 
 
 
Figure 23: Analysis of pAKT expression in Huh7 cells after treating with higher doses of 
NVP-BEZ235. 
Analyse the expression of pAKT in higher concentrations of NVP-BEZ235 for 48hrs was 
performed with western blotting. β actin was used as an internal loading control.  
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4.1.5: Synergistic effect of combination treatment using PI3K/mTOR 
molecular target inhibitors on cell proliferation inhibition 
 
Cytostatic effect of RAD001 treatment on Huh7 cells, could lead the cells resistant to 
RAD001 treatment, as is the case in hepatocellular carcinoma patients (Ref). 
Therefore, the effect of combinatorial treatment of drugs that target either PI3K 
pathway alone (NVP-BKM120) or PI3K/mTOR pathway (NVP-BEZ235) with RAD001 
was further investigated. Combination treatment of RAD001 with either NVP-BKM120 
or NVP-BEZ235 significantly showed a synergistic effect on cell proliferation inhibition 
(Figure 24). Combination treatment led to almost 50% more inhibition on cell 
proliferation when compared to the single treatment. Thereby, combination treatment 
led to the Huh7 cell demise.   
 
 
 
 
 
Figure 24: Effect of combination treatment of PI3K/mTOR inhibitors on cell proliferation 
of Huh7 cells. 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with using IC50 of RAD001, NVP-BKM120 and NVP-
BEZ235 for 48hrs and cell proliferation was measured by MTT assay.   
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4.1.6: Synergistic effect of combination treatment using PI3K/mTOR 
molecular target inhibitors with chemotherapeutic drugs on cell 
proliferation inhibition 
 
HCC patients were also treated with chemotherapeutic drugs, which were shown to 
have a moderate effect on controlling HCC. So, the next aim was to analyse the 
synergistic effect of PI3K/mTOR molecular target inhibitors in combination with 
classical chemotherapeutic drugs like doxorubicin, cisplatin, 5FU and irinotecan on 
Huh7 cell proliferation. Huh7 cells were treated with either RAD001 or NVP-BKM120 
or NVP-BEZ235 in combination with chemotherapeutic drugs. MTT assay results 
clearly indicate that cisplatin and irinotecan combination with RAD001 had a significant 
influence on inhibiting cell proliferation compared to 5FU and doxorubicin combination 
(Figure 25, 26 and 27). The combination of RAD001 with cisplatin/irinotecan had an 
extra 50% inhibition compared to cisplatin/irinotecan single treatments. 
 
 
 
Figure 25: Effect of combination treatment of mTOR inhibitor (RAD001) and 
chemotherapeutic drugs on cell proliferation of Huh7 cell lines. 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with using IC50 of RAD001 and combination of 
chemotherapeutic drugs for 48hrs and cell proliferation was measured by MTT assay. ** 
indicates P<0.01 between single drug treatment vs combination treatment. 
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Figure 26: Effect of combination treatment of PI3Kinhibitor (NVP-BKM120) and 
chemotherapeutic drugs on cell proliferation of Huh7 cell lines. 
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with using IC50 of NVP-BKM120 and combination of 
chemotherapeutic drugs for 48hrs and cell proliferation was measured by MTT assay. ** 
indicates P<0.01 between single drug treatment vs combination treatment. 
 
Figure 27: Effect of combination treatment of PI3K\mTOR inhibitor (NVP-BEZ235) and 
chemotherapeutic drugs on cell proliferation of Huh7 cell lines.  
Huh7 cells were seeded in 96 well plates at a density of 1X104 cells per well and were grown 
for 16 hrs. Then the cells were treated with using IC50 of NVP-BEZ235 and combination of 
chemotherapeutic drugs for 48hrs and cell proliferation was measured by MTT assay. ** 
indicates P<0.01 between single drug treatment vs combination treatment. 
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4.1.7: PI3K/mTOR molecular target inhibitors alone and in 
combination with chemotherapeutic drugs enhanced the inhibition 
of respective signalling cascades in Huh7 cells 
 
The results from the cell proliferation assays clearly showed that combination 
treatment had a potential effect in inhibiting Huh7 cell proliferation, therefore molecular 
mechanisms involved in this phenomenon were elucidated. Major downstream targets 
of PI3K/mTOR pathway, P-S6R, 4E-BP1 and upstream signalling protein AKT 
phosphorylations were analyzed after the treatment of Huh7 cells with PI3k/mTOR 
inhibitors in combination with chemotherapeutic drugs. Combination of 
chemotherapeutic drugs with either RAD001 (Figure 28) or NVP-BEZ235 (Figure 30) 
dephosphorylated 4E-BP1 and P-S6 ribosomal protein expression, whereas in the 
case of AKT, phosphorylation of AKT was upregulated due to the inhibition on mTOR  
negative feedback loop mechanism. In Huh7 cells treated with NVP-BKM120 and 
chemotherapeutic drugs combination, 4E-BP1 and P-S6 ribosomal protein 
dephosphorylation was enhanced whereas phosphorylation of AKT was decreased 
(Figure 29). 
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Figure 28: Analysis of P-S6R, 4E-BP1 and pAKT expression in Huh7 cells after treating 
with combination of mTOR inhibitor RAD001 and chemotherapeutic drugs. 
Huh7 cells were seeded in 10cm petridish at a density of 1.5X106 cells and were grown for 16 
hrs. Then the cells were treated with using IC50 of RAD001 and combination of 
chemotherapeutic drugs for 48hrs, cells were harvested and western blotting was performed for 
indicated markers. β actin was used as an internal control. 
 
 
 
 
 
 
Figure 29: Analysis of P-S6R, 4E-BP1 and pAKT expression in Huh7 cells after treating 
with combination of PI3K inhibitor NVP-BKM120 and chemotherapeutic drugs. 
Huh7 cells were seeded in 10cm petridish at a density of 1.5X106 cells and were grown for 16 
hrs. Then the cells were treated with using IC50 of NVP-BKM120 and combination of 
chemotherapeutic drugs for 48hrs, cells were harvested and western blotting was performed for 
indicated markers. β actin was used as an internal control. 
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Figure 30: Analysis of P-S6R, 4E-BP1 and pAKT expression in Huh7 cells after treating 
with combination of PI3K/mTOR inhibitor NVP-BEZ235 and chemotherapeutic drugs. 
Huh7 cells were seeded in 10cm petridish at a density of 1.5X106 cells and were grown for 16 
hrs. Then the cells were treated with using IC50 of NVP-BEZ235 and combination of 
chemotherapeutic drugs for 48hrs, cells were harvested and western blotting was performed for 
indicated markers. β actin was used as an internal control. 
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4.1.8: PI3K/mTOR molecular target inhibitors alone and combination 
with cisplatin led to cell cycle arrest in Huh7 cells 
 
As per the cell proliferation assay results cisplatin and irinotecan showed significant 
synergistic effect in combination with PI3K/mTOR molecular target inhibitors in 
inhibiting Huh7 cell proliferation. As cisplatin is in use of clinical trials  further studies 
were carried with cisplatin. To evaluate the antiproliferative activity and the effect on 
cell cycle by the PI3K/mTOR molecular target inhibitors alone and in combination with 
cisplatin in Huh7 cells, flow cytometric analysis was performed.  Treatment of Huh7 
cells with PI3K/mTOR molecular target inhibitors resulted in a higher accumulation of 
cells in G1 phase, with RAD001 arresting 53.6% of cells, NVP-BKM 120 and NVP-
BEZ235, arresting 54.8% and 50.65% of cells in G1 phase (Figure 31). Cisplatin 
treatment led to accumulation of cells in S phase (56.9%) when compared to control 
(42.1%). Furthermore, in combination treatment cell cycle was arrested between G1 
and S phase (Figure 32).  
 
 
Figure 31: Assessment of cell cycle arrest by combination of PI3K/mTOR inhibitors and 
cisplatin. 
Huh7 cells were synchronized by tight contact inhibition among them, then splitted and treated 
with indicated drugs for 24hrs and cell cycle experiment was performed by FACS calibre. % of 
G0\G1 phase population was analyzed with flowJo software. 
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Figure 32: Assessment of cell cycle arrest by combination of PI3K/mTOR inhibitors and 
cisplatin. 
Huh7 cells were syncronized by tight contact inhibition among them, then splitted and treated 
with indicated drugs for 24hrs and cell cycle experiment was performed by FACS calibre. % of 
S phase population was analyzed with flowJo software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74 
4.1.9: PI3K/mTOR molecular target inhibitors alone and in 
combination with cisplatin led to apoptosis induction in Huh7 cells 
 
As cell proliferation inhibition could be due to cell cycle arrest/induction of apoptosis/ 
induction of autophagy/ necrosis, induction of apoptosis was studies in Huh7 cells after 
the drug treatment by annexin V/PI staining (Figure 33). Qauntification of apoptosis 
identified more apoptotic cells in RAD001 (5.3%), NVP-BKM120 (5.8%), NVP-BEZ235 
(4.9%) and cisplatin (6.9%) treatments compared to control (3.74%). Combination of 
cisplatin with RAD001 (12.8%), NVP-BKM120 (9.51%) and NVP-BEZ235 (13.7%) 
showed increased apoptotic cells compared to single treatment (Fig 34).  
 
 
 
 
Figure 33: Assessment of apoptosis induction by combination of PI3K/mTOR inhibitors 
and chemotherapeutic drugs. 
Huh7 cells were seeded in 6 well plate at a density of 0.25X106 cells per well and were grown 
for 16 hrs. Then the cells were treated with using IC50 of indicated drugs for 48hrs, cells are 
harvested, stained with AnnexinV\PI and apoptosis in cells was analyzed by FACS calibre. 
Data was analyzed with flowJo software. Data represents one out of two experiments done. 
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Figure 34: Quantification of apoptosis induction by combination of PI3K/mTOR 
inhibitors and cisplatin. 
After analyzing the cells on FACS calibre (n=2) data was quantified with flowJo software. 
  
4.1.10: PI3K/mTOR inhibitors induced tumor regression in xenograft 
model 
 
In vitro data in Huh7 cells clearly showed that the combination of PI3K/mTOR 
molecular target inhibitors in combination with cisplatin plays significant role in 
inhibiting cell proliferation compared to their respective single treatments. Further 
studies were carried out to check the efficacy of these drugs in vivo by using nude 
mouse xenograft model. Nude mice were injected at the flank region with Huh7 cells 
and followed for tumor development. When tumor size reached 5mm size in any 
direction, then the mice were treated with respective drugs. Anti-tumor activity was 
observed in xenograft model after treatment with PI3K/mTOR molecular target 
inhibitors (Figure 35A). Tumor volume was effectively reduced in RAD001 (408 mm3), 
NVP-BKM120 (69.9 mm3) and NVP-BEZ235 (276.3 mm3) treated mice compared to 
control (1485 mm3) mice (Figure 35B). NVP-BKM120 had a prolific influence on tumor 
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regression followed by NVP-BEZ235 and RAD001. However, NVP-BKM120 treated 
mice were less healthy compared to other treated mice.  
 
 
 
 
 
Figure 35: Analysis of tumor growth of Huh7 xenograft by PI3K/mTOR inhibitors 
RAD001, NVP-BKM120 and NVP-BEZ235. 
A) Huh7 cells were subcutaneously injected into the nude mouse in a flank region on one side 
and when tumors are 5mm in size in any direction, treatment was started with RAD001 
10mg\Kg, NVP-BKM120 60mg\kg and NVP-BEZ235 45mg\Kg body weight on every day for 2 
weeks. Representative pictures of tumor bearing mice after treatment period are shown here. 
B) Statistical representation of tumor volume of treated and control xenograft mice. 
 
Tumor tissues from treated mice revealed great differences in morphology 
demonstrated by HE staining. Control mice and RAD001 treated mice showed more 
necrosis when compared to NVP-BKM120 and NVP-BEZ235 treated mice. Among 
treated tumor tissues, RAD001 treated tumors had more necrosis compared to all 
(Figure 36).  
 
Immunohistochemistry results using Ki67 marker illustrated more population of 
proliferating cells in control tumor samples compared to treated mice (Figure 26). 
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pHis3 marker is one of the most prominent cell proliferation markers used to 
distinguish the proliferating cell population from non proliferating cell population. 
Immunohistochemistry results clearly showed the difference between treated and 
control tumor samples. Treated tissue samples have less pHis3 cells compared to 
control tissues. TUNEL staining results illustrated that there are a few more apoptotic 
cells in treated tissues compared to control (Figure 36). Quantification of the stainings 
showed that among the three drugs NVP-BKM120 and NVP-BEZ235 have a potential 
effect on tumor regression compared to RAD001 (Figure 37). 
 
 
 
 
Figure 36: Histopathological analysis of Huh7 xenograft tumor tissue treated with 
PI3K/mTOR inhibitors RAD001, NVP-BKM120 and NVP-BEZ235. 
Pathological analysis of tumor tissues treated with RAD001 10mg\Kg, NVP-BKM120 60mg\kg 
and NVP-BEZ235 45mg\Kg body weight on every day for 2 weeks using H&E, Ki67, pHis3 and 
Tunel staining. 
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Figure 37: Quantification of histopathological data in Huh7 xenograft tumor tissue 
treated with PI3K/mTOR inhibitors RAD001, NVP-BKM120 and NVP-BEZ235. 
Analysis of  statistical data of pathological analysis of tumor tissues treated with RAD001 
10mg\Kg, NVP-BKM120 60mg\kg and NVP-BEZ235 45mg\Kg body weight on every day for 2 
weeks using H&E, Ki67, pHis3 and Tunel staining. ** indicates P< 0.01 between control vs 
treated mice.  
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4.1.11:  Effect of PI3K/mTOR molecular target inhibitors on 
angiogenesis in xenograft tumor tissue 
 
Angiogenesis markers were examined to assess the expression status of CD31 and 
αSMA. It was known that CD31 is mainly involved in endothelial cell to cell interaction 
and drives angiogenesis. αSMA is generally expressed in smooth muscle cells of 
blood vessels.  Immunohistochemistry with anti-CD31 and anti- αSMA clearly showed 
no difference in treated versus control tissues (Figure 38). 
 
 
 
 
Figure 38: Angiogeneis analysis in xenograft tumor tissue upon treatment with 
PI3K/mTOR inhibitors RAD001, NVP-BKM120 and NVP-BEZ235. 
Double staining for CD31 (green) and α-SMA (red) of cryosectioned tumor samples treated 
either with RAD001 10mg\Kg, NVP-BKM120 60mg\kg and NVP-BEZ235 45mg\Kg body weight 
on every day for 2 weeks. CD31-positive tumor vessels are partially covered by α-SMA-positive 
pericytes (arrows) and contain α-SMA-positive fibrotic areas (arrow heads). Scale bar 
represents 100 µm.  
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4.1.12: Effect of PI3K/mTOR molecular target inhibitors on 
expression of molecular markers in mouse xenograft tissues 
 
To investigate the phosphorylation of AKT, tumors were harvested 1hr post treatment 
with NVP-BEZ235 and NVP-BKM120. Western blots were performed for checking the 
phosphorylation status of P-S6R, 4E-BP1 and AKT in mouse xenografts. The results 
clearly showed a strong dephosphorylation of P-S6R, 4E-BP1 in treated tumors 
compared to control tumors and no difference in pAKT expression in treated and 
control samples (Figure 39). 
 
 
 
 
 
 
Figure 39: Analysis of mTOR markers and phospo-AKT expression in tumor tissues after 
treatment with RAD001, NVP-BKM120 and NVP-BEZ235. 
Protein was isolated from tumor tissues treated with RAD001 10mg\Kg, BKM 60mg\kg and BEZ 
45mg\Kg body weight on every day for 2 weeks and western blotting was performed for P-S6R, 
4E-BP1, pAKT and βactin was an internal loading control. 
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4.1.13: Effect of PI3K/mTOR molecular target inhibitors on 
expression of other kinase pathways in mouse xenograft tissues 
 
After checking the phosphorylation status of downstream markers of PI3K\mTOR 
pathway, we checked the expression status of p-JNK, c-JUN, p-P38, and p-ERK to 
assess the possible cross talk mechanism activation by RAD001, NVP-BKM120 and 
NVP-BEZ235. Western blot analysis clearly showed that there was no difference of p-
JNK, c-JUN and p-P38 expression between treatment and control tissue samples. But 
pERK was showed activation in treated samples compared to control (Figure 40). 
 
 
 
 
Figure 40: Analysis of JNK and MAPK pathway expression in tumor tissues after treating 
with RAD001, NVP-BKM120 and NVP-BEZ235.  
Protein was isolated from tumor tissues treated with RAD001 10mg\Kg, NVP-BKM120 60mg\kg 
and NVP-BEZ235 45mg\Kg body weight on every day for 2 weeks and western blotting was 
performed for p-JNK, c-jun, p-p38, p-ERK and βactin was used as an internal loading control. 
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4.1.14: Effect of PI3K/mTOR molecular target inhibitors on 
expression of cell cycle related proteins in mouse xenograft tissues 
 
Cell cycle related proteins like cyclins expression was next analyzed.  It was noticed 
that cyclin A and cyclin D1 were significantly down regulated in treated samples 
compared to control samples. It strongly confirms the G0/G1 phase arrest in cell cycle 
upon RAD001, NVP-BKM120 and NVP-BEZ235 treatment. CyclinB1 protein 
expression was also less in RAD001 treatment compared to control, whereas NVP-
BKM120 and NVP-BEZ235 treatment had more down regulation than RAD001. In 
addition to these proteins p21 expression was analyzed. p21 protein expression was 
down regulated upon RAD001 treatment but not in NVP-BKM120 and NVP-BEZ235 
treatment (Figure 41).  
 
 
 
 
Figure 41: Analysis of cell cycle related proteins expression in tumor tissues after 
treating with RAD001, NVP-BKM120 and NVP-BEZ235. 
Protein was isolated from tumor tissues treated with RAD001 10mg\Kg, NVP-BKM120 60mg\kg 
and NVP-BEZ235 45mg\Kg body weight on every day for 2 weeks and western blotting was 
performed for cyclin A, cyclin B1, Cyclin D, p21 and βactin was used as an internal loading 
control. 
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4.1.15: Combination of PI3K/mTOR molecular target inhibitors with 
cisplatin induced tumor regression in xenograft model 
 
Tumor regression was significantly enhanced in combination treatment of PI3K/mTOR 
inhibitors with cisplatin compared to single treatment (Figure 42A and B). Tumor 
volume was significantly reduced in combination of NVP-BKM120 with cisplatin 
(28.9mm3) compared to NVP-BEZ235 with cisplain (42.3mm3) and RAD001 with 
cisplatin (68.3mm3) (Figure 42B).  
 
 
 
Figure 42: Analysis of tumor growth by combination of PI3K/mTOR inhibitors and 
cisplatin in Huh7 xenograft tissues. 
A). Huh7 cells were subcutaneously injected into the nude mouse in a flank region on one side 
and when tumors are 5mm in size at any direction, treatment was started with the combination 
of RAD001 10mg\Kg, NVP-BKM120 60mg\kg, NVP-BEZ235 45mg\Kg body weight on every 
day for 2 weeks and with cisplatin 3mg\Kg body weight once in a week for 2 weeks. 
Representative pictures are of tumor bearing mice after treatment period. B) Statistical 
representation of tumor volume of treated and control xenograft mice. 
 
HE staining displayed larger necrotic areas in control and in mice treated with RAD001 
in combination with cisplatin, compared to NVP-BKM120 and NVP-BEZ235 
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combination with cisplatin. Immunohistochemistry results explained the less population 
of proliferating cells in combination treated tumor samples by ki67 marker and pHis3 
compared to single drug treated mice. TUNEL staining revealed more apoptotic bodies 
in combination treated samples compared to single drug treated tumor samples 
(Figure 43). Qunatification of the stainings showed that the combination treatment had 
more advantage compared to single cisplatin treatment (Fig 44).  
 
 
 
 
 
Figure 43: Histopathological analysis of Huh7 xenograft tumor tissue treated with 
combination of PI3K/mTOR inhibitors with cisplatin. 
Pathological analysis of tumor tissues treated with RAD001 10mg\Kg, NVP-BKM120 60mg\kg, 
NVP-BEZ235 45mg\Kg body weight on every day for 2 weeks and with cisplatin 3mg\Kg body 
weight once in a week for 2 weeks using H&E, Ki67, pHis3 and Tunel staining. 
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Figure 44: Histopathological analysis of Huh7 xenograft tumor tissue treated with 
combination of PI3K/mTOR inhibitors with cisplatin. 
Analysis of  statistical data of pathological analysis of tumor tissues treated with the 
combination of RAD001 10mg\Kg, NVP-BKM120 60mg\kg, NVP-BEZ235 45mg\Kg body weight 
on every day for 2 weeks and with cisplatin 3mg\Kg body weight once in a week for 2 weeks 
using H&E, Ki67, pHis3 and Tunel staining.  
** indicates P< 0.001 and * indicates P< 0.01 between control vs treated. 
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4.1.16: Molecular markers expression in tumor tissue treated with 
the combination of PI3K/mTOR molecular target inhibitors with 
cisplatin 
 
P-S6 ribosomal protein was completely dephosphorylated in combination treated 
samples compared to cisplatin alone. 4E-BP1 dephosphorylation was observed more 
in combination treated samples compared to cisplatin alone (Figure 45). 
 
 
 
 
Figure 45: Analysis of mTOR markers and pAKT expression in tumor tissues treated 
with combination of PI3K/mTOR inhibitors with cisplatin. 
Protein was isolated from tumor tissues treated with RAD001 10mg\Kg, NVP-BKM120 
60mg\kg, NVP-BEZ235 45mg\Kg body weight on every day for 2 weeks and with cisplatin 
3mg\Kg body weight once in a week for 2 weeks and western blotting was performed for P-
S6R, 4E-BP1, pAKT and βactin was used as an internal loading control. 
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4.2: Therapeutic approaches of Hepato Cellular Carcinoma by 
identification of molecular targets of RAD001 sensitivity and 
resistance in HCC cell lines  
 
In recent years, RNA interference (RNAi) studies became one of the most powerful 
tools to identify and characterize novel drug resistant and sensitive candidate genes. 
This drug resistance was noticed in many HCC patients and due to this poor treatment 
response there is a need of new gene targets to improve the treatment of HCC. 
Therefore, in this part of the study, screening of the broad range of human genome 
library pool for RAD001 resistant and sensitive genes was aimed. In principle, RAD001 
forms a complex with FKBP12 and binds to mTOR and leads to dephosphorylation of 
4E-BP1 and P70S6K and ultimately down regulation of cell proliferation and 
metabolism. A working method of shRNA screening was first established, in which 
FKBP12 was silenced using shRNA against FKBP12 gene.  
 
4.2.1: Amplification of shRNAs by PCR  
 
shRNA oligos targeted against FKBP12 gene were (791, 764, 472, 689, 262 and 740) 
first amplified with specially designed EcoR1 and Xho1 primers and amplified products 
were confirmed on agarose gel (Figure 46). Number of each oligo denotes the oligo 
construction based on starting position on the mRNA.  
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Figure 46: Amplification of FKBP12 shRNA oligoes by PCR . 
shRNA oligos were amplified by specific restriction enzyme site primers which are EcoR1 and 
Xho1, amplified products were confirmed  on 2% agarose gel. 
 
4.2.2: Cloning of shRNA oligoes directed against FKBP12  
 
FKBP12 shRNA oligos were cloned into MLP vector using the EcoR1 and Xho1 sites 
present in the multiple cloning site of the plasmid (moloney murine vector under 
puromycin selection). Restriction digestion of the clones, was performed with EcoR1 
and Xho1 and the release of inserts were confirmed (Figure 47). Further confirmation 
was carried out by DNA sequencing using mir30 primers. Midiprep was performed in 
order to produce more amount of plasmid DNA for further retroviral transfection.  
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Figure 47: Confirmation of FKBP12 shRNA oligoes clones by restriction digestion. 
FKBP12 shRNA oligos clones were restriction digested with EcoR1 and Xho1 for 2hr at 37°C 
and the insert release was confirmed on 2% agarose gel. The figure represents two out of 6 
clones that showed insert release. 
 
4.2.3: Retroviral transfection of shRNAs lead to silencing the 
FKBP12 gene  
 
Once cloning of the FKBP12 shRNA was confirmed, retrovirus was prepared using 
phoenix cells as packaging cells. This virus was efficiently transduced into the Huh7 
cells and transduced cells were successfully selected in the presence of puromycin. 
After transduction, the silencing effect of shRNAs on FKBP12 gene was confirmed with 
RAD001 treatment. In figure 48, it was clearly showed that 262 shRNA was able to 
silence FKBP12 in Huh7 cells among all shRNAs. When FKBP12 was silenced, 
RAD001 treatment was not able to inhibit the mTOR which leads to the activation of 
mTOR down stream targets like P-S6 proteins and thereby leading to normal cell 
proliferation and metabolism. Schematic picture in Figure 49 shows the mechanism 
which explains the strategy behind the confirmation of FKBP12 silencing by P-S6 
protein expression after RAD001 treatment.  
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Figure 48: Confirmation of FKBP12 silencing by western blotting. 
Transduced cells with shRNA oligos were treated with RAD001 for 24hrs, then protein was 
harvested and western blotting was performed for P-S6 protein to find out the FKBP12 
silencing. 
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Figure 49: Schematic representation of mTOR pathway after using RAD001 when 
FKBP12 gene was silence. 
In the case of FKBP12 silencing, RAD001 mediated mTOR inhibition is lost there by the 
downstream mTOR targets will be activated leading to cell proliferation and metabolism. 
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4.2.4: GFP enrichment of FKBP12 silenced (262 shRNA) Huh7 cells 
in presence of RAD001 treatemnt 
 
In order to confirm, whether FKBP12 silencing in Huh7 cells might have any kind of 
regulation on cell proliferation after RAD001 treatment, cell population was maintained 
as 1:1000 ratios of FKBP12 silenced and normal Huh7 cells. 3 days after RAD001 
treatment Huh7 cells showed 2.66% GFP population where as in control it was 2.13% 
(Figure 50 A). 5 days of RAD001 treatment also had shown increment in GFP 
population compared to control (3.93 % vs 2.36 %) (Figure 50 B) and it was more 
compared to 3 days treatment. Furthermore, GFP population was even increased in 
10 days RAD001 treatment (8.37 %) compared to 3 days and 5 days RAD001 
treatment (Figure 50 C).  
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Figure 50: GFP enrichment in competition. 
FKBP12 silenced Huh7 cells (262 shRNA) and normal Huh7 cells were mixed at a ratio of 
1:1000 and co-cultured for A) 3days, B) 5 days and C) 10 days with RAD001 and assessed the 
GFP enrichment by flow cytometry. 
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4.2.5: RAD001, NVP-BKM120 and NVP-BEZ235 molecular target 
inhibitors effect on FKBP12 silenced (262 shRNA) Huh7 cell 
proliferation 
 
Cell proliferation assay (MTT) was carried out using IC50 concentration of molecular 
target inhibitors on FKBP12 silenced Huh7 cells. As expected, RAD001 treatment did 
not have any effect on cell proliferation inhibition in FKBP12 silenced Huh7 cells. NVP-
BEZ235 treatment had a partial inhibitory effect on proliferation.  Contrary, NVP-
BKM120 showed a significant effect on inhibiting cell proliferation (Figure 51).   
 
 
       
 
Figure 51: Comparison of cell proliferation between FKBP12 silenced Huh7 cells and 
normal Huh7 by MTT assay. 
FKBP12 silenced cells and control cells were plated in 96 well plates at a density of 1×104 cells 
and grown for 16hrs. Then the cells were treated with respective IC50 concentrations of 
RAD001, NVP-BKM120 and NVP-BEZ235 for 48hrs and cell proliferation was measured by 
MTT assay. Black bar represents Huh7 cells and grey bar represents FKBP12 silenced Huh7 
cells. 
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4.2.6: PI3K/mTOR molecular target inhibitors treatment resulted in 
the inhibition of respective signalling cascades in FKBP12 silenced 
Huh7 cells 
 
As expected, RAD001 treatment was not able to suppress the P-S6 ribosomal protein 
expression in FKBP12 silenced Huh7 cells. Contrary, NVP-BKM120 and NVP-BEZ235 
treatments led to dephosphorylation of P-S6 ribosomal protein expression (Figure 52).  
 
 
 
Figure 52: Analysis of P-S6R expression in FKBP12 silenced Huh7 cells after treating 
with RAD001, NVP-BKM120and NVP-BEZ235. 
FKBP12 silenced Huh7 cells were plated at a density of 1.5×106 cells and grown for 16 hrs. 
Then the cells were treated with respective IC50 concentrations of RAD001, NVP-BKM120 and 
NVP-BEZ235 for 48hrs, after treatment protein was isolated and western blotting was 
performed with P-S6R. β actin was used as an internal loading control.  
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4.2.7: Screening of genome wide library containing shRNAs in Huh7 
cells in presence of RAD001 
 
Pool of 5000 shRNAs was successfully transformed into electro competent E. Coli 
cells by electroporation. In order to confirm the transformation of all the 5000 shRNAs, 
transformed cells were plated as described in methods. Maxipreps were done to 
prepare large amount of plasmid DNA. Then using this pool of plasmids, lentivirus was 
produced using 293T cells.  Lentiviral transfection was carried out in order to 
transduce the cells with shRNAs. As a positive control for transduction, 293T cells are 
also transduced along with Huh7 cells as they are known to be highly transducible 
cells. Standardisation of  the MOI (Multiplicity of Infection) for virus was done in a way 
that transduced  cells will receive a single virus particle which contains only one 
shRNA was achieved (Figure 53). Later on, transduced cells were selected under 
puromycin selection, subjected to RAD001 and placebo treatment for 10 days. 
Genomic DNA was isolated from 10 days RAD001 and Placebo treated Huh7 
transduced cells. Genomic DNA will be subjected to solexa sequencing in order to find 
out novel resistant and sensitive target candidates towards mTOR inhibition by 
RAD001. 
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Figure 53: Assessment of 10-15% lenti virus MOI in Huh7 cells. 
Huh7 cells were seeded in T25 flask at a density of 2.75 X106 cells and were grown for 16 hrs. 
Then the cells were treated with virus for 24hrs and then trypsinized, cell fluorescence intensity 
was measured by FACS calibre and analysis was performed with flowJo software. 
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5 Discussion 
 
PI3K/mTOR pathway is one of the most pivotal signalling transduction cascade, 
involved in important physiological functions like cell metabolism, cell growth, cell 
proliferation, cell survival and angiogenesis (Cantley 2002). It was noticed that this 
pathway was either constitutively activated or deregulated in several cancers 
(Engelman et al. 2006; Yuan and Cantley 2008; Yuan et al. 2008). Since this pathway 
is involved in several signalling mechanisms, it was considered as a pathway that can 
be targeted for developing therapeutics in cancer treatment (Cantley 2002) and in fact, 
it was highly deregulated in HCC progression. The aim of this study was to target 
PI3K/mTOR pathway in HCC, by its specific kinase inhibitors and in combination with 
chemotherapeutic drugs. Inhibitors against PI3K/mTOR pathway provided appreciable 
growth arrest in Huh7 and HepG2 cells and were even more enhanced with 
combination of chemotherapeutic drugs. Combination of PI3K/mTOR inhibitors with 
cisplatin and irinotecan had a significant synergistic effect on HCC cell growth 
inhibition. In this study we also found that Huh7 cells when treated with RAD001 
showed a cytostatic effect on cell proliferation, which shows that these cells are 
resistant to RAD001 treatment.  In general, few HCC patients are found resistant to 
RAD001 treatment. Recent studies showed that functional genetic approach identifies 
the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer 
(Berns et al. 2007). We therefore aimed to unravel novel resistant genes for RAD001 
treatment in HCC, by genome-wide shRNA screen in Huh7 cells.  
 
5.1 Application of PI3K/mTOR inhibitors for HCC treatment 
 
The major etiologies of HCC are hereditary genetic mutations, viral hepatitis, chronic 
exposure to toxins, excessive alcohol consumption and/or deregulation of kinase 
pathways. In the case of deregulated kinase pathways in HCC, PI3K/mTOR pathway 
is considered to be one of the pioneering pathways that is highly deregulated. A 
number of drugs have been evaluated in clinical trials for HCC, of which RAD001 
(analogue of rapamycin) has emerged out with its specific efficiency and is still in 
phase trails. One of the most prominent features of advanced and metastatic HCC is 
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increased threshold level of proliferation. PI3K/mTOR pathway plays a pivotal role in 
cell proliferation, which makes this pathway as an ideal target in treating HCC. 
RAD001, a specific inhibitor of mTOR pathway, promotes the inhibition of HCC 
proliferation (Buitrago-Molina et al. 2009). But the drawback of using RAD001 is the 
negative feedback loop on AKT pathway, as it renders the phosphorylation of AKT and 
could not able to eliminate HCC progression completely (Guertin and Sabatini 2007).  
Guertin et al. showed that negative feedback loop inhibition occurs due to the 
connection between S6 kinase and insulin receptor substrate-1 (IRS1) and that 
activates AKT kinase following suppression of mTOR.  
 
In this study we showed that treatment of Huh7 cells with RAD001 led to a cytostatic 
effect (from 5nM-1000nM) on cell proliferation (Figure 13). This cytostatic effect could 
be due to the genetic instability of this cell line or on the other hand it could be due to 
the RAD001 inhibition of negative feedback loop of AKT. Indeed the results from Huh7 
cells clearly showed a significant increase in phosphorylated AKT expression after 
RAD001 treatment (Figure 22). In contrast to this, there was no difference in 
phosphorylated AKT levels between control and treated xenograft tissue samples 
(Figure 39). Treatment of RAD001 led to completely dephsophorylated P-S6 R and 
partial dephosphorylated 4E-BP1 in both in vitro and in vivo conditions (Figure 22 and 
39). HepG2 cells treated with RAD001 showed no significant effect on cell proliferation 
in a concentration range of 0.1-20µM, where as a strong dose dependent inhibitory 
effect on cell proliferation was observed between 30-60µM range (Figure 16). This 
clearly explains the differential sensitivities of cells to RAD001 treatment. As cytostatic 
effect of RAD001 on Huh7 cell proliferation was evident, which is a mimic condition to 
the resistance against RAD001 in HCC patients, and also Huh7 cells sensitiveness to 
lower concentrations of RAD001 compared to HepG2 cells, further studies were 
continued in Huh7 cells only. 
  
RAD001 is a well known mTOR inhibitor; therefore the downstream targets of mTOR 
in cells treated with RAD001 were analyzed. For this, P-S6 R and 4E-BP1, well 
charachaterized mTOR down stream proteins, were choosen and western blots for 
these proteins revealed complete dephosphorylation of P-S6 R and partial 
dephosphorylation of 4E-BP1 proteins (Figure 22), there by confirming the RAD001 
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effect on Huh7 cells. Studies done in HCC and other cancers showed that RAD001 
treatment promotes the inhibition of cell proliferation (Boulay et al. 2004; Beuvink et al. 
2005), which strongly supports the cell proliferation results in this study.  
 
In a previous study, subcutaneous patient-derived HCC xenografts were used to study 
the effects of RAD001 on tumor growth, proliferation, apoptosis and angiogenesis, 
reported that oral administration of RAD001 to mice bearing patient-derived HCC 
xenografts resulted in a dose-dependent inhibition of tumor growth (Huynh et al. 
2009). In order to check in vitro cell proliferation results with RAD001 treatment, in this 
study nude mouse xenograft models were used. Once the mice developed tumors, 
they were treated with RAD001 for 2 weeks and tumor growth was measured. RAD001 
treatment of xenograft tumors resulted in significant inhibition of tumor growth (Figure 
35), which supported in vitro cell proliferation data and is in accordance with previous 
studies. In addition to this other proliferation markers like Ki67 and p-His3 were 
analyzed (Figure 36). Quantification of positively stained cells showed that RAD001 
treatement led to a decrease in Ki67 and p-His3 stainings revealing that cell 
proliferation was arrested by RAD001. Histology studies of tumor tissues from mice 
treated with RAD001 revealed that there was no marked difference in necrosis when 
compared to control mice.  
 
Earlier studies done in cells showed that treatment with RAD001 resulted in increase 
of cells in G0/G1 phase of the cell cycle. Even at nanomolar concentrations of 
RAD001, there was a 10-70% increase in delaying progression at the early G0/G1 
phase in cell cycle (Vignot et al. 2005). In this study, treatment of Huh7 cells with 
RAD001 (50nM) resulted in the increase of cells in G0/G1 phase (Figure 31). Although 
preclinical studies have shown that rapamycin and its analogous are potent inhibitors 
of tumor cell proliferation leading to the accumulation of cells in G1 phase (Wendel et 
al. 2004; Wanner et al. 2006), the roles of specific down-stream pathways of mTOR 
have been poorly defined. So, therefore important proteins that regulate G1 phase of 
cell cycle were analyzed in xenograft tissues. 
 
In general, cyclinD1 is over expressed in several cancers and it plays a significant role 
in tumor progression. Previously, cyclinD1 was shown to regulate both growth and 
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proliferation downstream of mTOR in hepatocytes (Nelsen et al. 2003). In this study, 
RAD001 treatment resulted in down regulation of cyclinD1. In addition to this, cyclinA 
and the mitosis marker cyclinB1 were also down regulated upon RAD001 treatment. 
RAD001 treatment of Diffuse Large B-Cell Lymphoma (DLBCL) cells resulted in 
inducing G1phase arrest with an effect on cyclinD1 and other cyclin molecules like 
cyclinA during cell cycle regulation (Wanner et al. 2006).  Down regulation of these key 
markers clearly support the in vitro data in this study where Huh7 cells were arrested 
in G1 phase of the cell cycle (Figure 41). In a previous study, in addition to the down 
regulation of cyclins, p21 protein down regulation was observed upon treatment with 
RAD001 in Fah/p53 -/- mice (Buitrago-Molina et al. 2009). Analysis of p21 expression 
correlated well with the above study, showing a down regulation of p21 in xenograft 
tumor tissues treated with RAD001. 
 
As the results from cell proliferation and cell cycle analysis revealed that RAD001 
treatment leads to inhibition of cell proliferation and arrest of cells in G0/G1 phase, and 
also earlier studies had observed mTOR being a key regulator during apoptosis in 
cancer, RAD001 effect on apoptosis in Huh7 cells and xenograft tumor model was 
further analyzed. RAD001 treatment resulted in an increase of apoptotic cells in both 
Huh7 cells (Figure 33 and 34) and xenograft model (Figure 36 and 37). RAD001 
treated Huh7 cells showed moderately increased apoptotic cells compared to control 
cells which correlated well with an earlier study done in rapamycin treatment showed 
moderate activity on apoptosis in cancer cells (Tam et al. 2009).  
 
A cytostatic effect on Huh7 cell proliferation and a negative feedback loop activation of 
AKT after RAD001 treatment can be well correlated with the development of 
resistance against RAD001 in HCC patients. Therefore, new class of drugs were 
designed to target both PI3K and mTOR kinase proteins. So, thereby the dual inhibitor 
for PI3K and mTOR i.e NVP-BEZ235 and PI3K specific inhibitor i.e., NVP-BKM120 
were used to find out their effect on Huh7 cell proliferation and xenograft tumor model. 
NVP-BKM120 is being used for the first time in the treatment of liver cancer. As far as 
now there is only one published study where it was demonstrated that addition of the 
PI3K inhibitor NVP-BKM120 or the dual PI3K/mTOR inhibitor NVP-BEZ235 to the 
initial treatment with the Smo antagonist markedly delayed the development of 
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resistance (Buonamici et al. 2010). In this study new PI3K inhibitors were used instead 
of conventional PI3K inhibitors like wortmannin and LY294002, as it was already 
shown earlier, that these conventional drugs had a cross talk inhibition of other protein 
kinases and were toxic to cells (Stein 2001).  
 
Treatment of Huh7 cells with increasing doses of NVP-BEZ235 and NVP-BKM120 led 
to a dose dependent inhibition of cell proliferation (Figure 14 and 15). Among these 
two drugs NVP-BEZ235 was more effective at lower concentrations than NVP-
BKM120. The dual inhibitor NVP-BEZ235 was shown consistently more potent in 
inhibiting the proliferation of different cancer cells at concentrations >10 nM compared 
to RAD001 treatment (Serra et al. 2008). The results from this study were also in 
accordance with the above study as RAD001 had cytostatic effect from 5nM 
concentration and NVP-BEZ235 had a strong dose dependent inhibition of cell 
proliferation from 5nM-250nM range. Recent studies also showed, NVP-BEZ235 anti-
proliferative effect, on multiple myeloma cells (Baumann et al. 2009), melanoma cells 
(Marone et al. 2009) and in glioma cells (Liu et al. 2009). In the case of NVP-BKM120, 
this is the first study being conducted in HCC cells where we show that it inhibits Huh7 
cell proliferation at higher concentrations compared to RAD001 and NVP-BEZ235.  
 
In xenograft model, treatment with specified doses from the manufacturer resulted in 
increased tumor regression in the mice treated with NVP-BKM120 rather than NVP-
BEZ235 (Figure 35). But the mice treated with NVP-BKM120 were less healthy 
compared to RAD001 and NVP-BEZ235 treated mice. Maira et al., had also previously 
showed that chronic treatment of PC3M tumor-bearing animals with NVP-BEZ235 
twice a daily resulted in a statistically significant inhibition of tumor growth (Maira et al. 
2008), which supports the results in this study. Additionally another group using 
primary pancreatic cancer xenografts grown orthotopically, observed that acute oral 
dosing with NVP-BEZ235 strongly suppressed the phosphorylation of PKB/AKT and 
the growth of the tumors (Cao et al. 2009). In contrast in the present study, treatment 
of Huh7 cells with NVP-BEZ235 resulted in an increase of AKT phosphorylation, 
whereas both P-S6 and 4E-BP1 were dephosphorylated. Phosphorylation of AKT in 
NVP-BEZ235 treatment was due to IC50 concentration which inhibited only mTOR but 
not p-AKT, as it was observed that higher concentrations of NVP-BEZ235 significantly 
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dephosphorylated AKT (Figure 22 and 23). In xenograft tumor tissue, treatment of 
NVP-BKM120 and NVP-BEZ235 led to complete dephsophorylation of P-S6R, partial 
dephosphorylation of 4E-BP1 and dephosphorylation of p-AKT in xenograft tumor 
model. NVP-BKM120 treatment led to complete dephosphorylation P-S6R, 4E-BP1 
and pAKT in in vitro as well as in xenograft tumor tissues. 
 
NVP-BEZ235 and NVP-BKM120 treatment also resulted in a decrease of Ki67 and p-
His3 staining revealing that cell proliferation was arrested, which was comparable to 
that of RAD001 treatment. This shows that these drugs could be used alternative to 
RAD001 treatment, where RAD001 is not sensitive enough to control cancer 
progression. Histology studies of tumor tissues from mice treated with NVP-BEZ235 
and NVP-BKM120 revealed that there was less necrosis when compared to control 
and RAD001 treated mice.   
 
Treatment of Huh7 cells with NVP-BEZ235 and NVP-BKM120 resulted in the increase 
of cells in G0/G1 phase (Figure 31) whereas the percentage of cells in S phase were 
decreased (Figure 32). Initial studies done with NVP-BEZ235 using different types of 
cancer cells showed that upon NVP-BEZ235 treatment cells were arrested in G1 
phase of the cell cycle (Maira et al. 2008). In case of NVP-BKM120, this is the first 
study showing its effect on G0/G1 phase arrest in cell cycle. NVP-BEZ235 and NVP-
BKM120 treatment of mice carrying xenograft tumors resulted in down regulation of 
cyclinD1, cyclinA and cyclinB1 as was the case with RAD001. A very recent study 
showed that treatment of renal cell carcinoma cell line with NVP-BEZ235 resulted in 
complete suppression of cyclinD1 (Cho et al. 2010), which is in support to the above 
results.  Down regulation of these key markers clearly support the in vitro data where 
Huh7 cells were arrested in G1 phase of the cell cycle (Figure 41). Analysis of p21 
expression, showed no difference in regulation of p21 in xenograft tumor tissues 
treated with NVP-BEZ235 and NVP-BKM120. RAD001 showed a strong down 
regulation of p21 which shows that NVP-BEZ235 and NVP-BKM120 have different 
signalling mechanisms in arresting cell cycle, other than inhibiting cyclin proteins. In a 
recent study, RAD001 treatment of Fah/ p53-/- mice showed a strong down regulation 
of p21 expression in hepatocytes. Huh7 cells are well known p53 mutated cells, and 
the down regulation of p21 upon RAD001 treatment correlates well with the above 
 104 
study and at the same time it also confirms that at least NVP-BEZ235 and NVP-
BKM120 do not act through p53 signalling mechanism in arresting cells at G1 phase.  
 
Previous study in breast cancer cell lines showed that NVP-BEZ235 treatment resulted 
in apoptosis of these cell lines (Serra et al. 2008). In this study, Huh7 cells after 
treatment with NVP-BEZ235 and NVP-BKM120 showed an increase in number of 
apoptotic cells compared to control cells (Figure 33 and 34). NVP-BEZ235 and NVP-
BKM120 treated mice not only had more apoptotic cells than control mice but also 
more than RAD001 treated cells (Figure 36 and 37). This data further imposes the use 
of these drugs as an alternative to RAD001. 
 
Furthermore, potential influence of RAD001, NVP-BKM120 and NVP-BEZ235 on 
angiogenesis did not achieve success rate in this study. There was no difference in 
CD31 staining and αSMA staining between treated and control samples (Figure 38). In 
contrast to this, it was shown that NVP-BEZ235 treatment resulted in a potential 
inhibition of VEGF-induced cell proliferation and survival in vitro and VEGF-induced 
angiogenesis in vivo. Moreover, NVP-BEZ235 strongly inhibited micro vessel 
permeability both in normal tissue and in BN472 mammary carcinoma grown 
orthotopically in syngeneic rats. Similarly, tumor interstitial fluid pressure, a 
phenomenon that is dependent of tumor permeability, was significantly reduced with 
NVP-BEZ235 treatment (Schnell et al. 2008). Additionally, another study also showed 
that treatment with RAD001 diminished the expression of vascular endothelial growth 
factor in tumor-derived cell lines and inhibited angiogenesis in vivo (Mabuchi et al. 
2007).   
 
In this study, mTOR inhibition by RAD001 did not show any crosstalk with molecular 
mechanism like p38 and JNK pathways, but p-ERK level was upregulated in xenograft 
tumor tissues (Figure 40). In human cancer patients and in vivo mouse models 
phosphorylation of ERK was observed upon RAD001 treatment (Carracedo et al. 
2008). C-jun expression was unaltered in RAD001 treated xenograft tissues. Earlier 
studies showed that mTOR regulates c-Jun function during hepatocyte proliferation 
(Behrens et al. 2002; Eferl et al. 2003). Additionally, NVP-BKM120 and NVP-BEZ235 
also did not have any influence on c-Jun/JNK and p38 expression, but upregulation of 
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pERK was noticed (Figure 40). Recent studies showed that p70S6K-mediated, cross-
inhibitory regulation between the MEK/ERK and PI3K/mTOR pathways, in which each 
contribute to the maintenance of the self-renewal and tumorigenic capacity of 
glioblastoma cells (Sunayama et al. 2010).  
 
5.2 HCC treatment improvisation by combinatorial treatment 
with PI3K/mTOR inhibitors. 
 
Intrinsic sensitivity to rapamycin analogues between cell lines may vary by several 
orders of magnitude. Recent studies in multiple myeloma and other cancer cells using 
mTOR inhibitors showed an increase of basal AKT activation and phosphorylation, 
which is dependent on basal IGF-I/IGF-R signaling. IGF-I receptor inhibition prevented 
rapamycin-induced AKT activation and sensitized tumor cells to inhibition of mTOR 
(O'Reilly et al. 2006). As RAD001 treatment in Huh7 cells resulted in cytostatic effect 
on cell proliferation and also increase in basal AKT phosphorylation, we next aimed to 
find out the effect of RAD001 combination therapy with NVP-BKM120 and NVP-
BEZ235 on Huh7 cell proliferation. RAD001 in combination with NVP-BKM120 and 
NVP-BEZ235 resulted in a strong inhibition of cell proliferation in Huh7cells, compared 
to control and single treatments (Figure 24). Here it strongly implies that NVP-BEZ235 
had sensitized the RAD001 effect in Huh7 cells. These results were strongly supported 
in another study, where NVP-BEZ235 sensitized the lapatinib resistance (Eichhorn et 
al. 2008).  The combination of RAD001 with NVP-BKM120 led to complete 
dephsophorylation of P-S6 R protein which could be due to the RAD001, as RAD001 
alone had complete dephsophorylation of P-S6 R protein. But this combination had a 
synergistic effect on the dephsophorylation of 4E-BP1 and p-AKT (Figure 22). The 
combination of RAD001 and NVP-BEZ235 had synergistic effect on dephosphorylation 
of 4E-BP1, where they completely dephosphorylated 4E-BP1. However the 
combination of RAD001 and NVP-BEZ235 did not have any inhibitory effect on AKT 
phosphorylation. This could be due to the concentration of NVP-BEZ235 used for this 
study, as NVP-BEZ235 dephosphorylates AKT only at higher concentrations than its 
IC50 concentration (Figure 23). 
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5.3 HCC treatment improvisation by combination treatment of 
PI3K/mTOR inhibitors with classical chemotherapeutic drugs 
 
The ability of cancer cells to become resistant to anticancer agents remains a 
significant impediment to successful chemotherapy. Various clinical trials investigated 
the role of single-agent chemotherapy in patients with unresectable HCC and reported 
response rates varying from 0% to 20%. Combination of drugs is always congenial for 
better treatment of the cancer. In this study, it was clearly explained the efficient 
inhibition of cell proliferation by kinase inhibitors. Several chemotherapeutic agents 
have been evaluated for the treatment of HCC in the recent past; however, no single 
or combination chemotherapy regimen is particularly effective. Previous studies have 
shown that mTOR inhibition can restore the sensitivity to some conventional 
cheomtherapeutic drugs (Mabuchi et al. 2007). Therefore the effect of RAD001, NVP-
BKM120 and NVP-BEZ235 in combination with doxorubicin, cisplatin, 5FU or 
irinotecan on cancer cell viability was analyzed further. 
 
Treatment of Huh7 cells with chemotherapeutic drugs resulted in a dose dependent 
loss of cell viability. Interestingly the combination of RAD001 with doxorubicin, 
irinotecan and cisplatin significantly decreased Huh7 viability compared to single drug 
treatment. Additionally, cisplatin and irinotecan combination with RAD001 had 
significant reduction in cell proliferation (Figure 25). These results add further evidence 
to previous studies (Mabuchi et al. 2007; Saunders et al. 2010)  necessitating mTOR 
inhibition as an effective strategy to increase sensitivity of HCC to conventional 
chemotherapeutic drugs. In this study, the combination of NVP-BKM120 and NVP-
BEZ235 with doxorubicin, cisplatin, 5FU and irinotecan significantly decreased Huh7 
viability. Moreover, cisplatin and irinotecan combination with NVP-BEZ235 and/or 
NVP-BKM120 had a severe effect on inhibiting the cell proliferation (Figure 26 and 27). 
The best hallmark future of combination treatment in this study was the synergistic 
effect exhibited by PI3K/mTOR inhibitors and cisplatin/irinotecan, where combination 
treatment enhanced the loss of cell viability.  
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The combination of RAD001, NVP-BKM120 and NVP-BEZ235 with chemotherapeutic 
drugs led to complete or partial dephsophorylation of P-S6 R and 4E-BP1 (Figure 28, 
29 and 30). However, the combination of RAD001 and NVP-BEZ235 with 
chemotherapeutic drugs did not have any inhibitory effect on AKT phosphorylation, 
whereas NVP-BKM120 in combination with chemotherapeutic drugs showed a 
synergistic effect in inhibiting phosphorylation of AKT. 
 
RAD001 effect on the induction of apoptosis in cancer cells was shown to be 
moderately effect (Tam et al. 2009). In this study little apoptosis was observed after 
RAD001 treatment and it was further enhanced in combination with cisplatin (Figure 
34). Treatment of ovarian cancer cells with rapamycin sensitized the cells to cisplatin 
by inducing apoptosis (Schlosshauer et al. 2009).  RAD001 treatment sensitized the 
cisplatin induced apoptosis in an in vivo and in vitro model (Mabuchi et al. 2007) and in 
other study RAD001 treatment sensitized A549 cells (lung cancer cells) with wild type 
p53 to cisplatin induced apoptosis by inhibiting p21 translation in vitro (Beuvink et al. 
2005). In contrast, in the same study it had been shown that rapamycin sensitizes 
cisplatin-induced apoptosis in wild-type p53, but not mutant p53 tumour cells (Beuvink 
et al. 2005).  In this study, combination of NVP-BEZ235 and NVP-BKM120 with 
cisplatin resulted in an increase of apoptotic cells when compared to respective single 
treatments. NVP-BEZ235 has been evaluated in combination with conventional 
cytotoxic agents, thus showing promising efficacy with both doxorubicin and vincristine 
(Manara et al. 2010). These results further imply that a combination of PI3K/mTOR 
inhibitors with chemotherapeutic drugs will enhance the treatment of HCC. 
 
 
5.4 Identification of predictive and prognostic factors to 
improve cancer treatment by RNA interference screening of 
genome wide shRNAs. 
 
In vitro RNAi screening delineates new candidates for tumor suppression and 
oncogenesis. Cancer arises due to accumulation of many passenger and driver 
mutations as well as genetic instability and heterogenous nature. Today, there are no 
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effective drugs for curing liver cancer. Using integrative genomic and proteomic 
approaches in mouse models, new tumor supressors in liver cancer were identified 
(Lee et al. 2008; Zender et al. 2008). Another part of the present study dealt with 
unravelling novel oncogenes and tumor suppressors that are resistant to conventional 
RAD001 therapy in HCC, using genome wide shRNA screening by high throughput 
analysis. 
 
To approach this study, first an in vitro model system was established to check the 
functional status of shRNAs, which were designed in such a way that they possess 
mir30 sequence and long terminal repeats. microRNA-based short hairpin RNA are 
more potent triggers of the RNAi machinery and can efficiently suppress gene 
expression (Dickins et al. 2005; Silva et al. 2005). 
 
5.5 Functionally identifying the microRNA-Based FKBP12 short 
hairpin RNAs (FKBP12 shRNA) in HCC cell lines 
 
The procedure for constructing FKBP12 clones was performed (Figure 46 and 47) and 
suppressing the expression of FKBP12 gene using a retroviral-mediated approach 
was performed and silencing was confirmed with RAD001 treatment. In the absence of 
FKBP12, RAD001 did not have any effect on cell proliferation inhibition, therefore it 
was confirmed with P-S6 R protein expression, where 262 silenced cells showed P-
S6R protein expression (Figure 48 and 49). This kind of approach was well 
characterized in previous studies (Dickins et al. 2005; Silva et al. 2005; Liu et al. 
2009). 
Furthermore, evaluation of normal penetrance of the FKBP12 transduced cells was 
validated with GFP enrichment assay by pooling FKBP12 transduced cells and normal 
Huh7 cells with 1:1000 ratios under RAD001 treatment. Here it was noticed that GFP 
enrichment occurred day by day with the treatment of RAD001. After 3 days of 
RAD001 treatment showed 2.66% of GFP population, in 5 days treatment it was 
3.93% and in 10 days treatment it was notified 8.37% of GFP population (Figure 50).  
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Additional results of FKBP12 transduced cells in respect to proliferation studies with 
PI3K/mTOR inhibitors resulted in variable differences in the proliferation rate (Figure 
51). Here RAD001 treatment did not have any influence on inhibiting cell proliferation, 
where as NVP-BKM120 and NVP-BEZ235 had significant influence on inhibition of cell 
proliferation. Moreover, NVP-BKM120 and NVP-BEZ235 treatment resulted in 
complete dephosphorylation of P70S6 ribosomal protein but not in RAD001 treatment. 
These results additionally confirmed that there was no effect of RAD001 on FKBP12 
transduced cells (Figure 52).  
 
5.6 Genomic screen of shRNA libraries in Huh7 cells upon 
RAD001 treatment 
 
Electroporation studies enabled 12 pools, each pool of 5000 shRNAs. shRNAs very 
efficiently suppress gene expression when expressed from a single genomic copy in 
the cell (Dickins et al. 2005; Silva et al. 2005). In order to achieve this, standardisation 
of the MOI (Multiplicity of Infection) for virus to get a transduction efficiency of 10-15% 
was performed using FACS analysis (Figure 53). Furthermore, transduced cells were 
selected by puromycin and then subjected to RAD001 and placebo treatment for 10 
days. Genomic DNA was isolated from 10 days RAD001 and Placebo treated Huh7 
transduced cells. Genomic DNA will be subjected to solexa sequencing in order to find 
out novel resistant and sensitive target candidates towards mTOR inhibition by 
RAD001 (Zender et al. 2008). 
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6 Conclusion 
 
Though PI3K/mTOR inhibitors and chemotherapeutic drugs are tested as therapeutic 
agents in treating HCC, due to their effective role in controlling cancer progression, still 
they are not considered to be potent inhibitors of HCC progression because of the 
development of resistance to these drugs by HCC. Therefore it is of great interest to 
understand the key oncogenic markers and their mechanisms, which are involved in 
sensitizing the mechanisms of resistance in HCC. The first part of this study suggest 
that inhibition of PI3K by novel drug NVP-BKM120 led to potent tumor growth inhibition 
compared to RAD001 and NVP-BEZ235. NVP-BKM120 is one of its kinds of novel 
drug that is yet to be tested in liver cancers, which makes our study a significant one. 
Additionally, dual inhibition of PI3K/mTOR with NVP-BEZ235 is effective in preventing 
HCC proliferation and tumor growth as compared to RAD001 treatment alone. 
Combination of PI3K/mTOR inhibitors with cisplatin and irinotecan showed a strong 
synergistic activity indicating that combinatorial therapy using PI3K/mTOR and 
chemotherapeutic drugs could be a feasible option for non-cirrhotic HCC patients with 
good liver function.  In the second part of this study, a sucessful in vitro system was 
established to perform a genome-wide shRNA screen to unravel the novel genes 
responsible for drug resistance or sensitiveness to mTOR directed therapies in HCC. 
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8 Abbreviations 
 
AEC 3 amino-9-ethyl carbazol 
AMPK AMP-Activated Protein Kinase 
APS Ammonium per sulphate 
BSA Bovine serum albumin 
CDK Cyclin-Dependent Kinases 
DAPI 4’6-diamidino-2-phenyl indol 
DMEM Dulbecco's Modified Eagle Medium 
DNA Deoxyribonucleic acid 
4E-BP1 4E-Binding Protein 1 
eIF-4E Eukaryotic Initiation Factor 4E 
FACS Fluorescence activated cell sorter 
FAH Fumarylacetoaccetate Hydrolase 
HBV Hepatitis B Virus 
HCC Hepatocellular Carcinoma 
HCV Hepatitis C Virus 
H&E Hematoxylin and Eosin staining 
IGF Insulin-like Growht Factor 
IRS1 Insulin Receptor Substrate 1 
LB medium Luria Bertani medium 
MAPKK Mitogen-activated Protein Kinase Kinase 
mRNA Messenger ribonucleic acid 
mTOR mammalian Target of Rapamycin 
mTORC1 mTOC Complex 1 
mTORC2 mTOC Complex 2 
PI3K Phosphoinositide-3 Kinase 
pten Phosphatase and Tensin Homolog 
PVDF polyvinylidenfluoride 
RNA Ribonucleic acid 
RNAi Ribonucelic acid interference 
RPMI Roswell park memorial Institute 
S6 Ribosomal Protein S6 
S6K1 p70 Ribosomal Protien S6 Kinase 1 
shRNA Short hairpin RNA 
TEMED Tetramethyl ethylene di amin 
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